MDL | MFCD00930626 |
---|---|
Molecular Weight | 359.35 |
Molecular Formula | C15H22FN3O6 |
SMILES | O[C@H]1[C@@H](O)[C@H](N2C=C(C(NC(OCCCCC)=O)=NC2=O)F)O[C@@H]1C |
Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
DNA/RNA Synthesis [1]
Capecitabine is an anti-cancer chemotherapy drug. It is classified as an antimetabolite. Capecitabine is converted into 5′-deoxy-5-fluorocytidine (5′DFCR), 5′-deoxy-5-fluorouridine (5′DFUR) and 5-FU by carboxylesterases (CES1 and 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP), in both liver and tumour. Capecitabine induces a significant cytotoxic effect in vitro only at high concentrations. Mean IC 50 values vary from 860 μM in COLO205 cells to 6000 μM in HCT8 cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
A pharmacokinetic/pharmacodynamic study is carried out in mice bearing HCT 116 xenografts receiving 0.52 and 2.1 mmol/kg/d of Capecitabine by oral gavage. Capecitabine administered at 0.52 mmol/kg/day induces partial control of HCT 116 xenografts tumour growth: growth rate =7.5±0.5 on day 21. Capecitabine 2.1 mmol/kg/day achieves complete control of tumor growth during the treatment period: growth rate =1±0.2 on day 21 [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03428529 | Instituto Nacional de Cancer, Brazil |
Rectal Neoplasm Malignant
|
January 12, 2011 | Phase 2|Phase 3 |
NCT00496704 | Yonsei University|National Cancer Institute (NCI) |
Colorectal Cancer
|
January 2007 | Phase 1|Phase 2 |
NCT02560974 | Hoffmann-La Roche |
Gastric Cancer
|
June 2006 | Phase 3 |
NCT03997968 | Cyteir Therapeutics, Inc. |
Malignancy|Non-hodgkin Lymphoma|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Head and Neck Cancer|DLBCL|Mantle Cell Lymphoma|Follicular Lymphoma|Pancreatic Cancer|CLL|Small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Cancer
|
October 9, 2019 | Phase 1|Phase 2 |
NCT00706069 | Hellenic Oncology Research Group|University Hospital of Crete |
Metastatic Breast Cancer
|
June 2008 | Phase 1 |
NCT04556773 | AstraZeneca|Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited |
Metastatic Breast Cancer
|
December 17, 2020 | Phase 1 |
NCT00354523 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals |
Solid Tumor|Thyroid Cancer
|
December 2004 | Phase 1|Phase 2 |
NCT05536102 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Gastric Cancer
|
September 5, 2022 | Phase 2 |
NCT02415829 | Fudan University |
Colorectal Cancer
|
November 2014 | Phase 2 |
NCT00148135 | University of Michigan Rogel Cancer Center|Eli Lilly and Company |
Carcinoma of Unknown Primary
|
May 2001 | Phase 2 |
NCT04156698 | Eye & ENT Hospital of Fudan University |
Hypopharyngeal Carcinoma|Immunotherapy|Chemotherapy
|
May 21, 2020 | Phase 2 |
NCT00962312 | Cancer Trials Ireland |
Pancreatic Cancer
|
January 2009 | Phase 2 |
NCT04103697 | Blokhin´s Russian Cancer Research Center |
Rectal Neoplasms Malignant|Rectum Carcinoma|Rectal Cancer
|
August 1, 2019 | Phase 3 |
NCT02068131 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Metastatic Colorectal Cancer
|
February 2014 | Phase 2 |
NCT01525082 | Shaheen Shagufta|National Cancer Institute (NCI)|Stanford University |
Gastrinoma|Glucagonoma|Insulinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Recurrent Pancreatic Cancer|Somatostatinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
December 2012 | Phase 2 |
NCT02664103 | Sanofi |
Breast Cancer Metastatic
|
January 23, 2016 | Phase 2 |
NCT02344472 | Prof. W. Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation|University of Ulm |
Metastatic Breast Cancer
|
September 2015 | Phase 3 |
NCT02289547 | The Catholic University of Korea |
Stomach Neoplasms
|
May 2015 | Phase 3 |
NCT00578071 | Brian Czito|Amgen|Duke University |
Cancer of the Esophagus
|
December 2007 | Phase 1|Phase 2 |
NCT02592746 | Samsung Medical Center |
Metastatic Breast Cancer
|
June 2016 | Phase 2 |
NCT04856761 | Fudan University |
Biliary Tract Neoplasms|Recurrence|Cholangiocarcinoma|Gall Bladder Cancer
|
November 1, 2020 | |
NCT01969032 | Russian Academy of Medical Sciences |
Triple Negative Breast Cancer
|
August 2011 | Phase 2 |
NCT00006023 | Swiss Group for Clinical Cancer Research |
Prostate Cancer
|
March 2000 | Phase 2 |
NCT01024504 | Hellenic Oncology Research Group|University Hospital of Crete |
Metastatic Colorectal Cancer
|
March 2006 | Phase 2 |
NCT03117972 | Centre Hospitalier Universitaire de Besancon |
Metastatic Colorectal Cancer
|
August 4, 2017 | Phase 2 |
NCT00454636 | Hoffmann-La Roche |
Gastric Cancer
|
March 2007 | Phase 2 |
NCT00665457 | University of Nebraska|National Cancer Institute (NCI) |
Breast Cancer
|
April 2004 | Phase 2 |
NCT02595320 | Qamar Khan|University of Kansas Medical Center |
Breast Cancer|Gastrointestinal Cancer
|
October 5, 2015 | Phase 2 |
NCT05104866 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Cancer
|
October 18, 2021 | Phase 3 |
NCT02394535 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7
|
November 12, 2015 | Phase 1 |
NCT00469443 | Hellenic Oncology Research Group|University Hospital of Crete |
Colorectal Cancer
|
December 2006 | Phase 3 |
NCT03376659 | Georgetown University|Mayo Clinic|Indiana University|Emory University|National Cancer Institute (NCI)|George Mason University|Thomas Jefferson University|MedImmune LLC|Bavarian Nordic |
Metastatic Colorectal Cancer|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer
|
August 8, 2018 | Phase 1|Phase 2 |
NCT03588533 | Sung Yong Oh|Celltrion|Dong-A University Hospital |
HER-2 Positive Gastric Cancer|Metastatic Cancer
|
June 10, 2018 | Phase 2 |
NCT03503136 | Sun Yat-sen University|Tongji Hospital|Wuhan Union Hospital, China|Peking University|Air Force Military Medical University, China|Second Affiliated Hospital of Soochow University|The First Affiliated Hospital of Guangdong Pharmaceutical University|First People´s Hospital of Foshan|Fifth Affiliated Hospital, Sun Yat-Sen University|Cancer Hospital of Guizhou Province|Xiangya Hospital of Central South University|Jilin Provincial Tumor Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|Cancer Hospital of Guangxi Medical University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Zhejiang Cancer Hospital |
Nasopharyngeal Carcinoma
|
June 2018 | Phase 3 |
NCT00429871 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
May 2002 | Phase 3 |
NCT01130337 | Hoffmann-La Roche |
Gastric Cancer
|
July 2010 | Phase 2 |
NCT02002195 | International Group of Endovascular Oncology |
Metastatic Gastric Cancer
|
November 2013 | |
NCT02210364 | PharmaMar |
Metastatic Breast Cancer|Pancreatic Cancer|Metastatic Colorectal Cancer
|
April 2013 | Phase 1 |
NCT02598349 | Proton Collaborative Group|University of Florida Health |
Pancreatic Cancer
|
April 2016 | Phase 2 |
NCT04309578 | Asan Medical Center |
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
|
March 12, 2020 | Phase 2 |
NCT00303745 | Federation Francophone de Cancerologie Digestive|National Cancer Institute (NCI) |
Colorectal Cancer
|
June 2006 | Phase 2 |
NCT03578874 | The University of Hong Kong |
Hepatocellular Carcinoma
|
June 20, 2016 | Phase 2 |
NCT01126138 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Hoffmann-La Roche |
Carcinoma, Invasive Ductal, Breast
|
July 2010 | Phase 3 |
NCT02485834 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma|Gastric Cancer
|
August 2015 | Phase 2 |
NCT00398320 | Pamela L. Kunz|Stanford University |
Neuroendocrine Tumors
|
November 2006 | Phase 2 |
NCT00216437 | James A. Haley Veterans Administration Hospital|Hoffmann-La Roche |
Cancer of Liver
|
December 2004 | Phase 1 |
NCT04379596 | AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo |
Gastric Cancer
|
June 3, 2020 | Phase 2 |
NCT03563157 | ImmunityBio, Inc. |
Colorectal Cancer Metastatic|mCRC
|
May 25, 2018 | Phase 1|Phase 2 |
NCT00677443 | Samsung Medical Center|National Cancer Center, Korea|Seoul National University Bundang Hospital|Seoul National University Hospital|Gachon University Gil Medical Center|Yonsei University|Asan Medical Center|Chonnam National University Hospital |
Colorectal Cancer
|
June 2008 | Phase 3 |
NCT00964704 | Hoffmann-La Roche |
Breast Cancer
|
March 2011 | Phase 2 |
NCT01415336 | Peking Union Medical College Hospital |
Breast Cancer
|
March 2010 | Phase 2|Phase 3 |
NCT01993472 | Gu Yanhong|The First Affiliated Hospital with Nanjing Medical University |
Colorectal Neoplasms
|
November 2013 | Phase 2 |
NCT04188158 | Universidad de León |
Locally Advanced Colon Cancer
|
March 10, 2017 | Phase 2 |
NCT00052273 | Jonsson Comprehensive Cancer Center|Eli Lilly and Company |
Adult|Solid Tumor
|
December 2002 | Phase 1 |
NCT03779035 | Tianjin Medical University Cancer Institute and Hospital |
Cholangiocarcinoma|Gall Bladder Carcinoma
|
December 15, 2018 | Phase 3 |
NCT01374425 | Genentech, Inc. |
Colorectal Cancer
|
August 2011 | Phase 2 |
NCT03156036 | Asan Medical Center |
Advanced Rectal Cancer
|
November 30, 2017 | Phase 2 |
NCT00368329 | Stanford University |
Esophageal Neoplasms|Carcinoma, Squamous Cell|Adenocarcinoma|Esophageal Cancer
|
June 2006 | Phase 1 |
NCT00253565 | Herbert Hurwitz|National Cancer Institute (NCI)|Duke University |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2003 | Phase 1 |
NCT01917552 | Asan Medical Center|Ulsan University Hospital|Seoul National University Bundang Hospital|Gangnam Severance Hospital|Seoul National University Boramae Hospital|Ajou University School of Medicine|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Hallym University Medical Center|Inje University|Kyung Hee University Hospital|Gachon University Gil Medical Center|Kangbuk Samsung Hospital|Korea University Guro Hospital|Kyungpook National University Hospital |
Gastric Cancer
|
November 2013 | Phase 3 |
NCT03084939 | Hoffmann-La Roche |
Breast Cancer
|
April 24, 2017 | Phase 3 |
NCT01262469 | UNICANCER|GlaxoSmithKline |
Metastatic Breast Cancer|70 Years Old Patients and Over|After One Line of Chemotherapy With Trastuzumab
|
December 2009 | Phase 2 |
NCT00477464 | GlaxoSmithKline |
Metastatic Breast Cancer|Neoplasms, Breast
|
June 2007 | Phase 2 |
NCT01099527 | Samsung Medical Center |
Metastatic Gastric Cancer
|
October 2009 | Phase 1|Phase 2 |
NCT01043484 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Hoffmann-La Roche |
Rectal Cancer
|
December 2009 | Phase 2 |
NCT03329248 | ImmunityBio, Inc. |
Pancreatic Cancer
|
November 6, 2017 | Phase 1|Phase 2 |
NCT03986385 | Hebei Medical University |
Gastroesophageal Junction Adenocarcinoma
|
June 1, 2019 | Phase 3 |
NCT03415763 | LI XIN-XIANG|Fudan University |
Rectal Neoplasms
|
November 5, 2018 | Phase 3 |
NCT01503983 | Fundación para el Progreso de la Oncología en Cantabria |
Stage IV Gastric Cancer With Metastasis
|
August 2011 | Phase 2 |
NCT00503932 | M.D. Anderson Cancer Center |
Rectal Cancer
|
July 2007 | Phase 1|Phase 2 |
NCT03585465 | Centre Oscar Lambret|Anticancer Fund, Belgium|Bristol-Myers Squibb|CTD-CNO|ECS-Progastrin SA |
Childhood Solid Tumor
|
March 26, 2019 | Phase 1|Phase 2 |
NCT00290615 | Herbert Hurwitz|National Cancer Institute (NCI)|Duke University |
Colorectal Cancer
|
January 2006 | Phase 2 |
NCT04177602 | Universitätsklinikum Hamburg-Eppendorf|Clinical Trial Center North (CTC North GmbH & Co. KG)|Servier Affaires Médicales |
Locally Advanced Rectal Cancer
|
November 4, 2019 | Phase 1|Phase 2 |
NCT03387098 | ImmunityBio, Inc. |
Pancreatic Cancer
|
January 2, 2018 | Phase 1|Phase 2 |
NCT00182715 | Velindre NHS Trust|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2005 | Phase 3 |
NCT05111444 | Fudan University |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma
|
December 31, 2021 | Phase 2 |
NCT02007148 | International Group of Endovascular Oncology |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
November 2013 | Phase 2 |
NCT02720601 | New Mexico Cancer Care Alliance |
Biliary Tract Cancer
|
November 2015 | Phase 2 |
NCT03691051 | Henan Cancer Hospital |
HER2 Positive Metastatic Breast Cancer
|
November 20, 2018 | Phase 2 |
NCT01664494 | Hoffmann-La Roche |
Breast Cancer, Colorectal Cancer, Gastric Cancer
|
April 2010 | |
NCT01167738 | IRCCS San Raffaele |
Pancreatic Cancer
|
July 2010 | Phase 2 |
NCT01208103 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ampulla of Vater Adenocarcinoma|Small Intestinal Adenocarcinoma|Stage III Ampulla of Vater Cancer AJCC v8|Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Ampulla of Vater Cancer AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Ampulla of Vater Cancer AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IV Ampulla of Vater Cancer AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8
|
May 6, 2011 | Phase 2 |
NCT00925769 | Hoffmann-La Roche |
Pancreatic Cancer
|
January 2009 | Phase 1 |
NCT00347438 | University of Chicago|Breast Cancer Research Foundation|Roche Pharma AG |
Breast Cancer
|
September 2006 | Phase 2 |
NCT00087152 | National Cancer Institute (NCI) |
Breast Cancer
|
June 2004 | Phase 2 |
NCT05239169 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Biliary Tract Cancer (CCA)|Intrahepatic Cholangiocarcinoma|Hilar Cholangiocarcinoma|Distal Cholangiocarcinoma|Gall Bladder Carcinoma
|
May 23, 2022 | Phase 2 |
NCT03009058 | Immodulon Therapeutics Ltd |
Metastatic Cancer
|
May 24, 2017 | Phase 1|Phase 2 |
NCT04304352 | European Institute of Oncology |
Advanced Breast Cancer
|
July 29, 2011 | Phase 2 |
NCT01097265 | Jeroen Bosch Ziekenhuis|National Cancer Institute (NCI) |
Colorectal Cancer
|
July 2010 | Phase 2|Phase 3 |
NCT01782651 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2014 | |
NCT05291052 | The First Affiliated Hospital with Nanjing Medical University |
Biliary Tract Tumor
|
February 14, 2022 | Phase 2 |
NCT04509596 | Dizal Pharmaceuticals |
Breast Cancer Metastatic
|
September 21, 2020 | Phase 1 |
NCT00230399 | University of Michigan Rogel Cancer Center |
Colorectal Cancer
|
June 2003 | Phase 2 |
NCT00629148 | Fudan University |
Breast Cancer|Metastasis, Neoplasm
|
August 2007 | Phase 2 |
NCT01953003 | Pierre Fabre Medicament |
Malignant Neoplasm of Breast
|
September 2013 | Phase 3 |
NCT04165772 | Memorial Sloan Kettering Cancer Center|Tesaro, Inc. |
Rectal Adenocarcinoma|Clinical Stage: Stage II (T3-4, N-)|Stage III (Any T, N&addition;)|Solid Tumor|Solid Tumor, Adult
|
December 11, 2019 | Phase 2 |
NCT00193609 | SCRI Development Innovations, LLC|Roche Pharma AG|Sanofi-Synthelabo |
Neoplasms, Unknown Primary
|
September 2004 | Phase 2 |
NCT02910843 | Swiss Group for Clinical Cancer Research |
Rectal Cancer
|
February 22, 2017 | Phase 1 |
NCT02514681 | Japan Breast Cancer Research Group|Chugai Pharmaceutical |
HER2-positive Locally Advanced or Metastatic Breast Cancer
|
August 1, 2015 | Phase 3 |
NCT00711412 | Northwestern University |
Esophageal Cancer
|
May 31, 2006 | Phase 2 |
NCT00632489 | SCRI Development Innovations, LLC|Novartis |
Breast Cancer
|
May 2008 | Phase 1 |
NCT00305643 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Pfizer |
Breast Cancer|Colorectal Cancer|Pain
|
February 2006 | Phase 3 |
NCT02548195 | Shanghai Zhongshan Hospital |
Cholangiocarcinoma
|
July 2015 | Phase 3 |
NCT00626158 | University of California, San Francisco|National Comprehensive Cancer Network |
Pancreatic Cancer|Biliary Cancer
|
February 2008 | Phase 1 |
NCT05018182 | West China Hospital |
High-risk Locally Advanced Colorectal Cancer|Neoadjuvant Chemotherapy|FOLFOXIRI Regimen
|
August 2, 2021 | Phase 2 |
NCT00658593 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer
|
March 19, 2008 | Phase 3 |
NCT02551237 | UNICANCER |
Rectal Carcinoma
|
January 7, 2016 | Phase 3 |
NCT03169777 | ImmunityBio, Inc. |
Colorectal Cancer
|
August 2018 | Phase 1|Phase 2 |
NCT02280694 | HaEmek Medical Center, Israel |
Colorectal Cancer
|
January 2015 | Phase 2 |
NCT04037241 | Sorrento Therapeutics, Inc. |
Malignant Tumor of Pancreas Metastatic to Liver
|
November 1, 2021 | Phase 2|Phase 3 |
NCT00415285 | Georgia Center for Oncology Research & Education|Sanofi |
Breast Neoplasms
|
December 2006 | Phase 2 |
NCT00717197 | University of Florida |
Malignant Glioma
|
July 2008 | Phase 2 |
NCT01776307 | Sumitomo Pharma Oncology, Inc. |
Colorectal Cancer
|
March 2012 | Phase 2 |
NCT00338039 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Pancreatic Cancer
|
September 2005 | Phase 2 |
NCT03073785 | Chi Lin, MD, PhD|National Cancer Institute (NCI)|University of Nebraska |
Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7
|
September 16, 2016 | Phase 2 |
NCT00021047 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
July 2001 | Phase 1|Phase 2 |
NCT01182142 | Kidney Cancer Research Bureau |
Metastatic Renal Cell Carcinoma
|
September 2007 | Phase 2 |
NCT01899118 | Zhejiang Cancer Hospital |
Locally Advanced Rectal Cancer
|
April 2013 | Phase 2 |
NCT00076609 | PhytoCeutica |
Hepatocellular Carcinoma|Liver Cancer
|
October 2003 | Phase 1|Phase 2 |
NCT01331928 | Taipei Veterans General Hospital, Taiwan |
Gastric Cancer
|
January 2011 | Phase 2 |
NCT03114085 | First Affiliated Hospital of Guangxi Medical University |
Hepatocellular Carcinoma
|
May 20, 2017 | Phase 2 |
NCT00008034 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
February 2000 | Phase 1 |
NCT00081289 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2004 | Phase 2 |
NCT01808573 | Puma Biotechnology, Inc. |
HER2&addition; Metastatic Breast Cancer (MBC)
|
March 29, 2013 | Phase 3 |
NCT01311050 | King Faisal Specialist Hospital & Research Center |
Metastatic Colorectal Cancer
|
January 2009 | |
NCT04047862 | BeiGene |
Locally Advanced and Metastatic Solid Tumors
|
August 26, 2019 | Phase 1 |
NCT02358356 | Australasian Gastro-Intestinal Trials Group |
Midgut Neuroendocrine Tumours|Pancreatic Neuroendocrine Tumours
|
November 2015 | Phase 2 |
NCT01273051 | Radboud University Medical Center |
Rectal Tumour
|
November 2010 | Phase 2 |
NCT01963702 | Fudan University |
Gastric Cancer
|
August 2012 | Phase 2 |
NCT04383275 | Fudan University |
Breast Cancer
|
May 15, 2020 | Phase 2 |
NCT03473639 | University of Virginia|Syndax Pharmaceuticals |
Metastatic Breast Cancer|Breast Cancer
|
January 29, 2019 | Phase 1 |
NCT04443348 | Alice Ho|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation|Translational Breast Cancer Research Consortium|Massachusetts General Hospital |
Triple Negative Breast Cancer|Hormone Receptor Positive (HR&addition;), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)
|
December 16, 2020 | Phase 2 |
NCT02360501 | Sun Yat-sen University |
Nasopharyngeal Neoplasms
|
January 2008 | Phase 2 |
NCT00829166 | Hoffmann-La Roche |
Breast Cancer
|
February 2009 | Phase 3 |
NCT02678182 | Royal Marsden NHS Foundation Trust|MedImmune LLC|Clovis Oncology, Inc.|Eli Lilly and Company |
Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Gastro-oesophageal Junction|Adenocarcinoma of the Stomach
|
February 2015 | Phase 2 |
NCT02931890 | The Netherlands Cancer Institute |
Gastric Cancer
|
December 21, 2017 | Phase 2 |
NCT02287129 | Technical University of Munich |
Adenocarcinoma of the Esophagogastric Junction
|
November 2014 | Phase 2 |
NCT04262635 | Sun Yat-sen University |
Colorectal Cancer
|
September 1, 2020 | Phase 3 |
NCT00847119 | Institut Català d´Oncologia|Hoffmann-La Roche |
Rectal Cancer
|
September 2007 | Phase 2 |
NCT00113230 | M.D. Anderson Cancer Center|Genentech, Inc. |
Rectal Cancer
|
February 2005 | Phase 2 |
NCT00483834 | University Health Network, Toronto|Hoffmann-La Roche |
Colorectal Cancer
|
December 2006 | Phase 2 |
NCT01279681 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Cognitive+Functional Effects|Colorectal Cancer|Neurotoxicity
|
January 2011 | Phase 3 |
NCT00820222 | Novartis Pharmaceuticals|Novartis |
Metastases, Brain
|
April 14, 2009 | Phase 3 |
NCT00972881 | University College, London |
Rectal Cancer
|
April 2009 | Phase 1|Phase 2 |
NCT00101686 | Pfizer |
Colorectal Neoplasms
|
February 2003 | Phase 3 |
NCT04664829 | National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore |
Metastatic Triple-Negative Breast Carcinoma
|
October 1, 2020 | Phase 1 |
NCT00551213 | Merck Sharp & Dohme LLC |
Colorectal Cancer
|
November 21, 2007 | Phase 2 |
NCT00003867 | Montefiore Medical Center|National Cancer Institute (NCI) |
Cancer
|
March 1999 | Phase 1 |
NCT01955629 | Sanofi|Regeneron Pharmaceuticals |
Colorectal Cancer Metastatic
|
December 2013 | Phase 1|Phase 2 |
NCT00058318 | Southwest Oncology Group|National Cancer Institute (NCI) |
Kidney Cancer
|
December 2004 | Phase 2 |
NCT01298401 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Pancreatic Cancer
|
February 2012 | Phase 1 |
NCT01193517 | M.D. Anderson Cancer Center|Celgene |
Colorectal Cancer
|
August 2010 | Phase 1|Phase 2 |
NCT00121277 | University Health Network, Toronto|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 2005 | Phase 1 |
NCT00080301 | R-Pharm |
Breast Cancer|Metastases
|
September 2003 | Phase 3 |
NCT04406857 | National Cancer Institute (NCI) |
Locally Advanced Rectal Carcinoma|Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8
|
October 7, 2020 | Phase 1 |
NCT03887130 | Pierre Fabre Medicament |
Breast Cancer
|
March 2006 | Phase 2 |
NCT03300544 | National Cancer Institute (NCI) |
Locally Advanced Rectal Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Rectal Adenocarcinoma|Stage III Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7
|
September 20, 2017 | Phase 1 |
NCT03577392 | Sichuan Provincial People´s Hospital|Jiangsu Simcere Pharmaceutical Co., Ltd. |
Quality of Life
|
July 1, 2018 | Phase 2|Phase 3 |
NCT00040859 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
September 2002 | Phase 2 |
NCT00183898 | University of Southern California|Sanofi|Roche Global Development|Bristol-Myers Squibb |
Gastric Cancer|Esophageal Cancer
|
December 28, 2004 | Phase 2 |
NCT01108107 | Vejle Hospital|Herlev Hospital |
Colon Cancer
|
April 2010 | Phase 2 |
NCT04411706 | Xin-Hua Xu|China Three Gorges University, Yichang, China |
Hepatocellular Carcinoma
|
June 21, 2020 | Phase 2 |
NCT00198237 | Indiana University School of Medicine|Aventis Pharmaceuticals|Indiana University |
Breast Cancer
|
March 2003 | Phase 2 |
NCT02301143 | Celgene |
Pancreatic Neoplasms
|
April 21, 2015 | Phase 2 |
NCT03561740 | Sun Yat-sen University |
Breast Cancer
|
July 25, 2018 | Phase 3 |
NCT04248452 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Metastatic Esophageal Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Oligometastatic Esophageal Adenocarcinoma|Oligometastatic Gastric Adenocarcinoma|Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
|
February 6, 2020 | Phase 3 |
NCT00462865 | Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|University of New Mexico Cancer Center |
Breast Cancer
|
November 2007 | Phase 2 |
NCT00752063 | The University of Hong Kong |
Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma
|
September 2007 | Phase 2 |
NCT00118300 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Cervical Cancer|Endometrial Cancer|Ovarian Cancer|Vaginal Cancer
|
April 2005 | Phase 1 |
NCT00438100 | Japan Breast Cancer Research Network |
Breast Neoplasms
|
April 2008 | Phase 2 |
NCT02362958 | Sun Yat-sen University |
HER2 Positive Breast Cancer
|
January 9, 2015 | Phase 2 |
NCT03645876 | Jiangsu HengRui Medicine Co., Ltd. |
Metastatic Colorectal Cancer
|
November 8, 2018 | Phase 2 |
NCT02526953 | Blokhin´s Russian Cancer Research Center |
Anus Neoplasms|Carcinoma, Squamous Cell|Anus Diseases|Neoplasms|Neoplasms, Squamous Cell|Carcinoma
|
January 2016 | Phase 3 |
NCT00868634 | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Arbeitskreis Klinische Studien|Roche Pharma AG |
Metastatic Breast Cancer
|
February 2009 | Phase 3 |
NCT04135781 | Zhejiang Cancer Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. |
Stomach Cancer
|
March 1, 2020 | Phase 3 |
NCT04864067 | Servicio de Salud Metropolitano Sur Oriente |
Rectal Cancer
|
June 9, 2021 | Phase 2 |
NCT03929666 | Zymeworks Inc. |
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
|
August 29, 2019 | Phase 2 |
NCT05152147 | Zymeworks Inc.|BeiGene, Ltd. |
Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma
|
December 2, 2021 | Phase 3 |
NCT04608786 | Lee´s Pharmaceutical Limited |
Biliary Tract Cancer
|
February 1, 2021 | Phase 1 |
NCT02694718 | Hoffmann-La Roche|Sanofi-Synthélabo (Schweiz) AG |
Rectal Cancer
|
March 2005 | Phase 2 |
NCT03015168 | General Hospital of Ningxia Medical University |
Rectal Cancer|Prognosis
|
January 2012 | |
NCT01450696 | Hoffmann-La Roche |
Gastric Cancer
|
December 2011 | Phase 3 |
NCT00954876 | Translational Genomics Research Institute|Eli Lilly and Company |
Metastatic Colorectal Cancer
|
August 2009 | Phase 2 |
NCT04357587 | Case Comprehensive Cancer Center |
Rectal Neoplasms
|
August 6, 2020 | Phase 1 |
NCT04696757 | Kangbuk Samsung Hospital |
Rectal Cancer|Chemoradiotherapy|Watch & Wait
|
February 1, 2018 | Early Phase 1 |
NCT00225056 | Oncology Specialties, Alabama |
Metastatic Breast Cancer
|
October 2003 | Phase 2 |
NCT00112918 | Hoffmann-La Roche|National Cancer Institute (NCI) |
Colorectal Cancer
|
December 2004 | Phase 3 |
NCT02954536 | Memorial Sloan Kettering Cancer Center |
Esophageal Cancer|Gastric Cancer
|
November 3, 2016 | Phase 2 |
NCT00514293 | Raghu Nandan, M.D., Inc|National Cancer Institute (NCI) |
Lung Cancer
|
January 2007 | Phase 2 |
NCT03213002 | Northwell Health |
Glioblastoma Multiforme (GBM)|Glioblastoma|Glioma of Brain|Glioblastoma, Adult|Brain Tumor|Brain Tumor, Primary|Brain Tumor Adult|Cancer|Brain Cancer
|
June 13, 2017 | Phase 1|Phase 2 |
NCT00532909 | Branimir Sikic|AstraZeneca|Stanford University |
Anal, Colon, and Rectal Cancers|Colorectal Neoplasms|Colon+Rectal Cancer
|
July 2006 | Phase 1 |
NCT02981342 | Eli Lilly and Company |
Pancreatic Ductal Adenocarcinoma
|
January 12, 2017 | Phase 2 |
NCT05108428 | H. Lee Moffitt Cancer Center and Research Institute|Viewray Inc.|Natera, Inc. |
Rectal Adenocarcinoma
|
October 23, 2021 | Early Phase 1 |
NCT00755534 | Hellenic Oncology Research Group|University Hospital of Crete |
Colorectal Cancer
|
November 2008 | Phase 2 |
NCT05555888 | Fudan University |
Early Low Rectal Cancer
|
November 1, 2022 | Phase 2 |
NCT00766155 | European Organisation for Research and Treatment of Cancer - EORTC |
Colorectal Cancer
|
August 2008 | Phase 3 |
NCT04675983 | Innovent Biologics (Suzhou) Co. Ltd. |
Gastric Adenocarcinoma
|
March 10, 2021 | Phase 3 |
NCT00661102 | Hoffmann-La Roche |
Breast Cancer
|
December 2008 | Phase 3 |
NCT02873195 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Metastatic Colorectal Carcinoma|Recurrent Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7
|
July 7, 2017 | Phase 2 |
NCT00083148 | Roswell Park Cancer Institute |
Breast Cancer
|
November 2002 | Phase 1 |
NCT00216138 | Hoosier Cancer Research Network|Sanofi|Hoffmann-La Roche|Walther Cancer Institute |
Head and Neck Cancer
|
March 2004 | Phase 2 |
NCT03813784 | Jiangsu HengRui Medicine Co., Ltd. |
Gastric Cancer|GastroEsophageal Cancer
|
March 7, 2019 | Phase 3 |
NCT01095003 | Pierre Fabre Medicament |
Breast Cancer
|
May 2009 | Phase 3 |
NCT01497392 | Roswell Park Cancer Institute|Novartis |
Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 29, 2012 | Phase 1 |
NCT00577057 | Hospital Authority, Hong Kong|Hong Kong Nasopharyngeal Cancer Study Group Limited |
Nasopharyngeal Neoplasms
|
September 2006 | Not Applicable |
NCT03326674 | Odonate Therapeutics, Inc. |
Breast Cancer
|
December 21, 2017 | Phase 3 |
NCT01333332 | University of Virginia |
Pancreatic Cancer
|
August 2010 | Phase 2 |
NCT04258163 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|First People´s Hospital of Foshan |
Metastatic Breast Cancer
|
January 1, 2019 | |
NCT00614653 | M.D. Anderson Cancer Center|Genentech, Inc. |
Pancreatic Cancer
|
January 2008 | Phase 1 |
NCT00107276 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
August 2005 | Phase 2 |
NCT01234337 | Bayer|Onyx Therapeutics, Inc. |
Breast Cancer
|
February 21, 2011 | Phase 3 |
NCT02746796 | Ono Pharmaceutical Co. Ltd |
Gastric Cancer
|
March 2016 | Phase 2|Phase 3 |
NCT00049244 | R-Pharm|National Cancer Institute (NCI) |
Breast Cancer
|
September 2002 | Phase 1 |
NCT02403544 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Sanofi |
Carcinoma, Hepatocellular
|
September 2013 | Phase 1 |
NCT03079427 | Asan Medical Center|Bundang CHA Hospital|Seoul St. Mary´s Hospital|Severance Hospital |
Cholangiocarcinoma|Biliary Tract Cancer|Adjuvant Chemotherapy|Capecitabine|Gemcitabine|Cisplatin
|
May 15, 2017 | Phase 2 |
NCT00365417 | NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute |
Breast Cancer
|
August 2006 | Phase 2 |
NCT00506844 | National Cancer Center, Korea |
Rectal Neoplasms|Neoadjuvant Treatment
|
May 2006 | Phase 2 |
NCT02650752 | Memorial Sloan Kettering Cancer Center|Queens Cancer Center of Queens Hospital|University of Michigan |
Metastatic Breast Cancer|Central Nervous System (CNS) Metastases
|
January 6, 2016 | Phase 1 |
NCT02901301 | Yonsei University |
Gastric Cancer
|
February 6, 2017 | Phase 1|Phase 2 |
NCT00506168 | National Cancer Center, Korea |
Colorectal Neoplasms|Secondary|Drug Therapy, Combination
|
November 2001 | Phase 2 |
NCT04859582 | Merck Sharp & Dohme LLC |
Stomach Neoplasms
|
November 8, 2018 | Phase 3 |
NCT03011060 | The First Hospital of Jilin University|First Hospital of China Medical University|The Second Affiliated Hospital of Harbin Medical University|Qingdao University|First Affiliated Hospital Xi´an Jiaotong University|Baotou Cancer Hospital |
Breast Neoplasm Female
|
December 2016 | Phase 3 |
NCT01554969 | Emory University|Synta Pharmaceuticals Corp. |
Rectal Cancer
|
May 2012 | Phase 1 |
NCT05387603 | Lund University Hospital |
Neuroendocrine Tumors
|
June 2022 | Phase 3 |
NCT01032057 | Lisette Nixon|Cardiff University |
Pancreatic Cancer
|
July 2009 | Phase 2 |
NCT00448552 | University of Miami |
Head and Neck Cancer
|
February 2004 | Phase 2 |
NCT05368051 | Beijing Friendship Hospital |
Colorectal Neoplasms
|
October 1, 2021 | |
NCT02213744 | Merrimack Pharmaceuticals |
Breast Cancer|HER2 Positive Breast Cancer
|
July 2014 | Phase 2|Phase 3 |
NCT02028494 | Latin American & Caribbean Society of Medical Oncology|Breast Cancer Research Foundation |
Breast Cancer
|
August 2013 | Not Applicable |
NCT01050322 | Latin American Cooperative Oncology Group|GlaxoSmithKline |
BRMS1|Performance Status Zero to Two for Beginning the Study|Patient With a Maximum of One Chemotherapy|Patient With Progression After Taxanes
|
November 2009 | Phase 2 |
NCT03423849 | Zhiyong Yu|Shandong Cancer Hospital and Institute |
Breast Cancer|Chemotherapy Effect|Disease-free Survival
|
February 8, 2018 | Phase 2|Phase 3 |
NCT02567331 | Hoffmann-La Roche |
Colorectal Cancer
|
October 2004 | Phase 4 |
NCT03204734 | Zhejiang Cancer Hospital |
Breast Cancer
|
January 1, 2016 | Phase 2 |
NCT02043821 | Beijing Chao Yang Hospital |
Metastatic Colorectal Cancer
|
Not Applicable | |
NCT03158610 | Ruijin Hospital |
Colorectal Cancer
|
January 29, 2018 | Phase 2|Phase 3 |
NCT04803539 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer
|
April 1, 2021 | Phase 2|Phase 3 |
NCT00081796 | Sanofi |
Breast Cancer|Metastases
|
April 2004 | Phase 3 |
NCT03396926 | University of California, San Francisco|Merck Sharp & Dohme LLC |
Microsatellite Stable|Mismatch Repair Protein Proficient|Stage III Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7
|
April 18, 2018 | Phase 2 |
NCT00087334 | Roswell Park Cancer Institute |
Colorectal Cancer
|
January 2004 | Phase 1|Phase 2 |
NCT04307147 | Fudan University |
Breast Cancer
|
July 3, 2018 | Phase 3 |
NCT01310985 | King Faisal Specialist Hospital & Research Center |
Colon Rectal Cancer Duke Stage Stageval
|
March 2008 | |
NCT03783442 | BeiGene |
Esophageal Squamous Cell Carcinoma (ESCC)
|
December 11, 2018 | Phase 3 |
NCT00561522 | Fudan University |
Hepatocellular Carcinoma|Neoplasm Metastasis
|
November 2007 | Phase 2|Phase 3 |
NCT02934529 | Ludwig-Maximilians - University of Munich |
Metastatic Colorectal Cancer
|
March 2015 | Phase 3 |
NCT02178644 | Yale University |
Rectal Cancer
|
July 2014 | Phase 1 |
NCT04274933 | AbbVie |
Breast Cancer|Cancer
|
May 21, 2020 | Phase 1 |
NCT05235542 | Akeso |
Advanced Malignant Tumors
|
July 12, 2022 | Phase 1|Phase 2 |
NCT04802980 | Huabo Biopharm Co., Ltd. |
Solid Tumor
|
April 28, 2020 | Phase 1 |
NCT00630045 | Peking University People´s Hospital|Peking University|Sanofi |
Colorectal Cancer|Resectable Liver Metastasis
|
January 2008 | Phase 3 |
NCT00871273 | Cambridge University Hospitals NHS Foundation Trust |
Adenocarcinoma of the Stomach
|
November 2009 | Phase 4 |
NCT00453323 | National Cancer Center, Korea |
Esophageal Cancer
|
June 2006 | Phase 2 |
NCT00249977 | University of New Mexico |
Solid Tumors|Cancer
|
April 2003 | Phase 1 |
NCT02010567 | UNC Lineberger Comprehensive Cancer Center|Cerulean Pharma Inc. |
Rectal Cancer
|
December 2013 | Phase 1|Phase 2 |
NCT05296005 | Ohio State University Comprehensive Cancer Center |
Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage II Gastric Cancer AJCC v8|Clinical Stage IIA Gastric Cancer AJCC v8|Clinical Stage IIB Gastric Cancer AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Pathologic Stage IB Gastric Cancer AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Gastric Cancer AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastric Cancer AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastric Cancer AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
|
May 31, 2022 | Phase 1 |
NCT00114153 | University of Virginia|National Cancer Institute (NCI) |
Head and Neck Cancer
|
June 2003 | Phase 1 |
NCT04780347 | Fudan University |
Breast Cancer
|
December 15, 2020 | Phase 2 |
NCT05089643 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Metastatic Triple-Negative Breast Cancer
|
April 11, 2019 | Phase 2 |
NCT00372944 | AstraZeneca |
Pancreatic Cancer
|
August 2006 | Phase 2 |
NCT00130507 | Spanish Breast Cancer Research Group|Hoffmann-La Roche |
Breast Cancer
|
November 4, 2005 | Phase 2 |
NCT00194792 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
August 2005 | Phase 2 |
NCT00416494 | Herbert Hurwitz, MD|National Cancer Institute (NCI)|Duke University |
Colorectal Cancer
|
September 2003 | Phase 2 |
NCT02414009 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Metastatic Colorectal Cancer
|
September 2014 | Phase 2 |
NCT05514275 | Zhejiang Cancer Hospital |
Nasopharyngeal Carcinoma
|
August 1, 2022 | Phase 2 |
NCT00257348 | University of California, Irvine|Aventis Pharmaceuticals |
Cervical Cancer
|
March 2004 | Phase 2 |
NCT00996333 | Columbia University|Sanofi |
Metastatic Pancreatic Cancer
|
June 2003 | Phase 2 |
NCT05566743 | Menoufia University |
Cancer of Pancreas
|
September 11, 2022 | Phase 2 |
NCT00297128 | Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche|Merck Gesellschaft mbH, Austria |
Rectal Cancer
|
October 2005 | Phase 2 |
NCT05507112 | Peking Union Medical College Hospital |
Locally Advanced Rectal Cancer
|
September 20, 2022 | Phase 2 |
NCT01494155 | Massachusetts General Hospital |
Pancreatic Cancer
|
December 2011 | Phase 2 |
NCT03153280 | Cancer Trials Ireland|University College Cork |
Colorectal Neoplasms|Stomach Neoplasm|Esophageal Neoplasms
|
January 13, 2022 | Phase 1 |
NCT03050814 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Colorectal Tumors|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Adenocarcinoma|Colorectal Cancer
|
April 5, 2017 | Phase 2 |
NCT03873532 | Hutchison Medipharma Limited|Hutchmed |
Biliary Tract Cancer
|
July 10, 2018 | Phase 2|Phase 3 |
NCT02892123 | Zymeworks Inc. |
HER2-expressing Cancers
|
September 2016 | Phase 1 |
NCT00684983 | National Cancer Institute (NCI)|Southwest Oncology Group |
HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
July 30, 2008 | Phase 2 |
NCT01783756 | Jonsson Comprehensive Cancer Center |
Central Nervous System Metastases|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
June 26, 2013 | Phase 1|Phase 2 |
NCT03349866 | Hebei Medical University |
Gastroesophageal Junction Adenocarcinoma
|
November 30, 2017 | Phase 2 |
NCT05172518 | Sun Yat-sen University|Chengdu Biostar |
Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer
|
March 1, 2022 | Phase 3 |
NCT04539808 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Borderline Resectable Pancreatic Carcinoma|Locally Advanced Unresectable Pancreatic Adenocarcinoma|Resectable Pancreatic Ductal Adenocarcinoma|Stage 0 Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8
|
May 27, 2021 | Phase 2 |
NCT01434147 | Austrian Breast & Colorectal Cancer Study Group|Hoffmann-La Roche |
Rectal Cancer
|
October 2011 | Phase 2 |
NCT02137356 | Sheba Medical Center|Karyopharm Therapeutics Inc |
Rectal Neoplasms
|
December 2014 | Phase 1 |
NCT00006465 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
December 2000 | Phase 1 |
NCT00321100 | Fox Chase Cancer Center |
Colorectal Neoplasms
|
April 12, 2006 | Phase 2 |
NCT03221426 | Merck Sharp & Dohme LLC |
Gastric Cancer|Gastroesophageal Junction Cancer
|
October 9, 2017 | Phase 3 |
NCT05062889 | Gruppo Oncologico del Nord-Ovest|Servier|Foundation Medicine |
Stage II Colon Cancer|Stage III Colon Cancer
|
December 2022 | Phase 2 |
NCT00338247 | Novartis |
Neoplasms, Breast
|
July 2006 | |
NCT03564912 | Zhejiang University |
Colorectal Cancer
|
August 12, 2018 | Phase 1|Phase 2 |
NCT01783444 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
February 26, 2013 | Phase 2 |
NCT00403429 | National Cancer Institute, Naples |
Ovarian Cancer
|
March 2006 | Phase 2 |
NCT00436241 | Hoffmann-La Roche |
Gastric Cancer
|
March 2007 | Phase 2 |
NCT00004183 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Malignant Mesothelioma
|
November 2000 | Phase 2 |
NCT00514761 | AstraZeneca |
Metastatic Colorectal Cancer
|
September 2006 | Phase 2 |
NCT00077077 | Daiichi Sankyo, Inc. |
Unspecified Adult Solid Tumor, Protocol Specific
|
February 2004 | Phase 1 |
NCT01677884 | Gustave Roussy, Cancer Campus, Grand Paris |
Colorectal Neoplasms
|
November 2012 | Phase 2 |
NCT00258232 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Colorectal Cancer
|
January 2002 | Phase 2 |
NCT01530503 | IRCCS San Raffaele|Regione Lombardia |
Biliary Tract Cancer
|
November 2011 | Phase 2 |
NCT02614794 | Seagen Inc. |
HER2 Positive Breast Cancer
|
January 28, 2016 | Phase 2 |
NCT02017704 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Nucletron |
Rectal Cancer
|
June 12, 2014 | Phase 2 |
NCT00207129 | R-Pharm |
Advanced Solid Tumors|Neoplasms
|
October 2004 | Phase 1 |
NCT01665274 | Harbin Medical University |
Gastric Cancer
|
September 2013 | Phase 2 |
NCT00086931 | Roswell Park Cancer Institute |
Colorectal Cancer
|
September 2003 | Phase 1|Phase 2 |
NCT02393755 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Boehringer Ingelheim|National Comprehensive Cancer Network |
Colon Adenocarcinoma|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
|
May 8, 2015 | Phase 1|Phase 2 |
NCT00816634 | Samsung Medical Center |
First Line Chemotherapy|Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel|Advanced or Recurrent Esophageal Squamous Cell Carcinoma
|
October 2008 | Phase 2 |
NCT04681911 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
September 9, 2020 | Phase 2 |
NCT00938470 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer|Gastric Cancer
|
January 2010 | Phase 2 |
NCT00058474 | NSABP Foundation Inc|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Colorectal Cancer
|
July 2004 | Phase 3 |
NCT02947061 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer Recurrent
|
April 2015 | Phase 2 |
NCT00824785 | Royal Marsden NHS Foundation Trust |
Oesophago-gastric Cancer
|
May 2008 | Phase 3 |
NCT00070122 | National Cancer Institute (NCI) |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
April 2004 | Phase 3 |
NCT01050985 | Georgetown University|Wyeth is now a wholly owned subsidiary of Pfizer |
Advanced Solid Tumors
|
July 2010 | Phase 1 |
NCT00077363 | National Cancer Institute (NCI) |
Recurrent Breast Cancer|Stage IV Breast Cancer
|
May 2004 | Phase 2 |
NCT00797485 | Southern Italy Cooperative Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
July 2008 | Phase 3 |
NCT01167049 | Peking University Cancer Hospital & Institute|Roche Pharma AG |
Gastric Cancer
|
August 2009 | Phase 2 |
NCT01887288 | Western Regional Medical Center |
Metastatic Breast Cancer
|
April 2013 | Phase 2 |
NCT01069796 | ARCAGY+ GINECO GROUP |
Triple Negative Metastatic Breast Cancer
|
April 2010 | Phase 2 |
NCT00812864 | University Hospital, Limoges |
Breast Cancer|Colorectal Cancer
|
January 2009 | Phase 4 |
NCT02736448 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Gastro-entero-pancreatic Neuroendocrine Tumors
|
May 2016 | Phase 2 |
NCT01439282 | Eisai Inc. |
Estrogen Receptor Positive Tumor|Breast Cancer
|
August 2011 | Phase 2 |
NCT03675737 | Merck Sharp & Dohme LLC |
Stomach Neoplasms
|
November 8, 2018 | Phase 3 |
NCT01225523 | Health Science Center of Xi´an Jiaotong University |
Squamous Carcinoma of Esophagus|Esophagus Disorders
|
January 1997 | Phase 1 |
NCT04371224 | Seoul National University Hospital |
Pancreatic Cancer
|
June 23, 2020 | Phase 2 |
NCT00177307 | University of Pittsburgh|Genentech, Inc. |
Cancer
|
January 2005 | Phase 2 |
NCT00583674 | Amgen |
Gastrointestinal Cancer
|
December 2007 | Phase 2 |
NCT05040360 | Southwest Oncology Group|National Cancer Institute (NCI) |
Metastatic Malignant Neoplasm in the Liver|Pancreatic Neuroendocrine Tumor|Stage I Pancreatic Neuroendocrine Tumor AJCC v8|Stage II Pancreatic Neuroendocrine Tumor AJCC v8|Stage III Pancreatic Neuroendocrine Tumor AJCC v8
|
October 14, 2021 | Phase 2 |
NCT00265733 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
February 2006 | Phase 2 |
NCT05177133 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Incyte Corporation |
Gastric Adenocarcinoma|Esophageal Adenocarcinoma
|
November 5, 2021 | Phase 2 |
NCT01500993 | Universitätsmedizin Mannheim |
Rectal Cancer
|
March 2002 | Phase 3 |
NCT01472770 | Vejle Hospital |
Metastatic Colorectal Cancer
|
October 2011 | Phase 2 |
NCT00217711 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
May 2005 | Phase 1|Phase 2 |
NCT00889187 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Pancreatic Cancer
|
December 2009 | Phase 1|Phase 2 |
NCT04095299 | Vejle Hospital |
Cancer of Rectum
|
January 20, 2020 | Phase 2 |
NCT00920868 | Herbert Hurwitz, MD|Bristol-Myers Squibb|Duke University |
Solid Tumor|Metastatic Colorectal Cancer
|
May 2009 | Phase 1 |
NCT01726452 | Cancer Trials Ireland|Southampton Clinical Trials Unit|Region H Rigshospitalet|Centre Hospitalier Régional, Universitaire de Lille |
Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Oesophago-gastric Junction|Oesophageal Tumours|Junctional Tumours|Oesophageal Cancer
|
January 24, 2013 | Phase 3 |
NCT01730222 | IRCCS San Raffaele |
Pancreatic Cancer
|
November 2012 | Phase 1|Phase 2 |
NCT01471353 | University of Florida|Bayer |
Colorectal Cancer Metastatic
|
November 2011 | Phase 2 |
NCT01380808 | Fudan University |
Metastatic Breast Cancer
|
May 2011 | Phase 2 |
NCT02715531 | Hoffmann-La Roche |
Solid Tumor
|
April 6, 2016 | Phase 1 |
NCT00601627 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Pancreatic Cancer
|
June 2009 | Phase 2 |
NCT00258284 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
August 2003 | Phase 2 |
NCT01589159 | Tao OUYANG|Peking University |
Metastatic Breast Cancer
|
January 2013 | Phase 2 |
NCT00088998 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
December 2004 | Phase 2 |
NCT00589901 | Fudan University |
Breast Cancer
|
August 2006 | Phase 2 |
NCT00953537 | Centre Antoine Lacassagne |
Breast Cancer
|
January 2009 | Not Applicable |
NCT02243007 | Massachusetts General Hospital |
Resectable Pancreatic Cancer|Pancreatic Ductal Carcinoma
|
September 2014 | Phase 2 |
NCT03641547 | University of Oxford|Merck KGaA, Darmstadt, Germany |
Oesophageal Adenocarcinoma|Squamous Cell Carcinoma|Solid Tumor
|
December 4, 2018 | Phase 1 |
NCT03878524 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic+Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma
|
April 1, 2020 | Phase 1 |
NCT01077427 | Klinikum der Universitaet Muenchen, Grosshadern|The European Society for Hyperthermic Oncology|Ludwig-Maximilians - University of Munich |
Resected Pancreatic Adenocarcinoma
|
March 2012 | Phase 3 |
NCT00193102 | SCRI Development Innovations, LLC|Celgene Corporation |
Breast Cancer
|
April 2001 | Phase 2 |
NCT00450515 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
March 2007 | Phase 2 |
NCT00454649 | Pfizer |
Neoplasms
|
December 2005 | Phase 1 |
NCT05374512 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Cancer
|
May 16, 2022 | Phase 3 |
NCT00743964 | Samsung Medical Center |
Advanced Gastric Cancer
|
April 2008 | Phase 2 |
NCT00960284 | IRCCS San Raffaele |
Pancreatic Cancer
|
June 2003 | Phase 2|Phase 3 |
NCT00411229 | Sanofi|Hoffmann-La Roche |
Stomach Neoplasms
|
June 2006 | Phase 3 |
NCT00997685 | Guangdong Provincial People´s Hospital |
Potentially Resectable Liver Metastasis From CRC|Colorectal Cancer
|
November 2009 | Phase 2 |
NCT00077857 | Hoffmann-La Roche |
Breast Cancer
|
July 2003 | Phase 2 |
NCT03930771 | Weill Medical College of Cornell University |
Recurrent Pituitary Adenomas
|
May 21, 2019 | Phase 2 |
NCT00268463 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Colorectal Cancer|Metastatic Cancer
|
January 2006 | Phase 3 |
NCT03925233 | Xijing Hospital |
Breast Cancer Organoids
|
January 2, 2019 | |
NCT00026234 | National Cancer Institute (NCI)|NSABP Foundation Inc |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
February 2002 | Phase 2 |
NCT01326481 | Tracon Pharmaceuticals Inc.|Roswell Park Cancer Institute|United States Department of Defense |
Metastatic Breast Cancer
|
June 2011 | Phase 1|Phase 2 |
NCT00718913 | Hellenic Oncology Research Group|University Hospital of Crete |
Gastric Cancer
|
April 2008 | Phase 2 |
NCT02973737 | Jiangsu HengRui Medicine Co., Ltd. |
HER2 Positive Metastatic Breast Cancer
|
July 20, 2016 | Phase 3 |
NCT05336721 | Chipscreen Biosciences, Ltd. |
Triple-negative Breast Cancer
|
November 5, 2021 | Phase 2 |
NCT00032175 | Cancer Research UK|National Cancer Institute (NCI) |
Pancreatic Cancer
|
April 2002 | Phase 3 |
NCT00562718 | University of Texas Southwestern Medical Center |
Breast Cancer
|
September 2004 | Phase 2 |
NCT00496366 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|HER2+Neu-positive Breast Cancer
|
July 23, 2007 | Phase 2 |
NCT01716949 | University of Erlangen-Nürnberg Medical School |
Rectal Cancer
|
September 2012 | Phase 1|Phase 2 |
NCT00966706 | IRCCS San Raffaele |
Pancreatic Cancer
|
June 2005 | Phase 2 |
NCT04663763 | Zhejiang Cancer Hospital |
Locally Advanced Rectal Cancer
|
December 1, 2020 | Phase 2 |
NCT00780494 | Pamela L. Kunz|Genentech, Inc.|Stanford University |
Stomach Cancer|Gastric (Stomach) Cancer|Neoplasm of Cardioesophageal Junction|Gastrointestinal Stromal Tumor (GIST)
|
February 2009 | Phase 2 |
NCT04262687 | Federation Francophone de Cancerologie Digestive |
Colorectal Cancer Metastatic|High Immune Infiltrate|Microsatellite Stable
|
April 6, 2021 | Phase 2 |
NCT00534417 | Accelerated Community Oncology Research Network|Hoffmann-La Roche|AstraZeneca |
Metastatic Breast Cancer
|
October 2007 | Phase 2 |
NCT02229149 | US Oncology Research|Genentech, Inc. |
Breast Neoplasms|Malignant Tumor of the Breast
|
December 2014 | Phase 2 |
NCT00276744 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
October 2005 | Phase 2 |
NCT04259944 | IFOM, The FIRC Institute of Molecular Oncology|Guardant Health, Inc. |
Colon Cancer
|
June 16, 2020 | Phase 2 |
NCT02028507 | Spanish Breast Cancer Research Group|Pfizer|AstraZeneca |
Metastatic Breast Cancer
|
March 13, 2014 | Phase 3 |
NCT01206049 | Vejle Hospital |
Cholangiocarcinoma
|
September 2010 | Phase 2 |
NCT02423954 | Western Regional Medical Center |
Advanced Cancer|Pancreatic Cancer|Renal Cell Cancer|Non Small Cell Lung Cancer|Colorectal Carcinoma|Endometrial|Uterine
|
April 2015 | Phase 1|Phase 2 |
NCT03044730 | Northwestern University|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) |
Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
|
May 25, 2017 | Phase 2 |
NCT01711242 | xie congying|Wenzhou Medical University |
Gastric Cancer
|
January 2012 | Phase 2 |
NCT00351195 | Rigshospitalet, Denmark|Morten Ladekarl, MD, DMSc., Dept. of Oncology, �rhus Sygehus, �rhus |
Hepatocellular Carcinoma
|
February 2006 | Phase 2 |
NCT04523818 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage IIA Gastric Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Gastric Adenocarcinoma|Pathologic Stage IB Gastric Cancer AJCC v8|Pathologic Stage II Gastric Cancer AJCC v8|Pathologic Stage IIA Gastric Cancer AJCC v8|Pathologic Stage IIB Gastric Cancer AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
|
August 11, 2020 | Phase 1 |
NCT00960544 | M.D. Anderson Cancer Center|Myriad Genetic Laboratories, Inc. |
Breast Cancer
|
January 2019 | Phase 2 |
NCT04908813 | Shanghai Henlius Biotech |
Gastric Cancer
|
September 29, 2021 | Phase 2 |
NCT02297230 | NYU Langone Health |
Breast Cancer
|
June 2002 | Phase 1|Phase 2 |
NCT00009737 | Hoffmann-La Roche |
Colorectal Cancer
|
November 1998 | Phase 3 |
NCT00329329 | Agennix |
Malignancies
|
May 2006 | Phase 1 |
NCT03872388 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2+Neu Negative|Inflammatory Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
January 14, 2019 | Phase 2 |
NCT01697072 | Amgen |
Gastric Cancer
|
October 2012 | Phase 3 |
NCT00290693 | University of Miami |
Pancreatic Cancer
|
July 2004 | Phase 2 |
NCT03708536 | Fujian Cancer Hospital |
Colorectal Adenocarcinoma
|
November 2018 | Phase 3 |
NCT00431106 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
April 2002 | Phase 3 |
NCT00177255 | University of Pittsburgh|Aventis Pharmaceuticals|Roche Pharma AG |
Cancer
|
April 2005 | Phase 2 |
NCT02294786 | Novartis Pharmaceuticals|Novartis |
Cancer
|
December 17, 2014 | Phase 2 |
NCT00511446 | Martin-Luther-Universität Halle-Wittenberg |
Stomach Neoplasms
|
August 2007 | Phase 2 |
NCT00070265 | National Cancer Institute (NCI) |
Liver Metastases|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer
|
August 2003 | Phase 2 |
NCT01015339 | Peking University|Roche Pharma AG |
Advanced Gastric Cancer
|
November 2009 | Phase 3 |
NCT03535727 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Adenocarcinoma|Pancreatic Neoplasms|Neoplasm, Glandular|Neoplasms|Neoplasms Pancreatic|Digestive System Neoplasm|Endocrine Gland Neoplasms|Digestive System Disease|Pancreatic Diseases|Endocrine System Diseases
|
June 21, 2018 | Phase 1|Phase 2 |
NCT03117855 | City of Hope Medical Center|National Cancer Institute (NCI) |
Bile Duct Adenocarcinoma|Stage III Intrahepatic Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma
|
December 2016 | Phase 1 |
NCT03777657 | BeiGene |
Gastric, or Gastroesophageal Junction Adenocarcinoma
|
December 13, 2018 | Phase 3 |
NCT03295084 | Dorte Nielsen|Herlev Hospital |
Metastatic Colorectal Cancer
|
July 15, 2015 | Phase 1 |
NCT00119171 | GlaxoSmithKline |
Solid Tumor Cancer
|
November 2004 | Phase 1 |
NCT02038621 | The Second People´s Hospital of Sichuan |
Advanced Gastric Cancer
|
January 2014 | Phase 2 |
NCT00074321 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 2003 | Phase 1 |
NCT00873353 | Grupo Gallego de Investigaciones Oncologicas |
Metastatic Adenocarcinoma of the Pancreas
|
March 2008 | Phase 2 |
NCT02633176 | Sun Yat-sen University|Chinese Southwest Oncology Group |
Nasopharyngeal Carcinoma
|
January 2015 | Phase 3 |
NCT05610163 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Locally Advanced Rectal Carcinoma|Stage II Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8
|
November 9, 2022 | Phase 2 |
NCT00070252 | National Cancer Institute (NCI) |
Adult Solid Neoplasm|Inflammatory Breast Carcinoma|Male Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer
|
September 2003 | Phase 1|Phase 2 |
NCT01611506 | Dr Anna Dorothea Wagner|Centre Hospitalier Universitaire Vaudois |
Gastric Cancer
|
February 2012 | Phase 1|Phase 2 |
NCT02013830 | Hoffmann-La Roche |
Liver Cancer
|
May 2005 | Phase 2 |
NCT03042000 | Peking Union Medical College Hospital|Beijing Hospital|Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking University People´s Hospital|Peking University Cancer Hospital & Institute|Beijing Friendship Hospital|Geneplus-Beijing Co. Ltd. |
Rectal Cancer, Adenocarcinoma|Neoadjuvant Chemoradiation
|
February 2017 | Not Applicable |
NCT02734290 | Providence Health & Services|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer
|
February 23, 2016 | Phase 1|Phase 2 |
NCT02137343 | Amgen |
Gastric Cancer
|
July 2014 | Phase 3 |
NCT00043121 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
June 2002 | Phase 1 |
NCT00345696 | Unidad Integral de Investigación en Oncología S.L.|Hoffmann-La Roche |
Metastatic Colorectal Cancer
|
June 2006 | Phase 2 |
NCT03818685 | Centre Leon Berard |
Breast Cancer|Triple Negative Breast Neoplasms
|
July 2, 2019 | Phase 2 |
NCT03563170 | ImmunityBio, Inc. |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent
|
May 25, 2018 | Phase 1|Phase 2 |
NCT01798251 | Harbin Medical University |
Gastric Cancer
|
December 2012 | Phase 2 |
NCT02854072 | Samsung Pharmaceutical Co., Ltd. |
Pancreatic Cancer
|
November 2015 | Phase 3 |
NCT01081262 | National Cancer Institute (NCI)|NRG Oncology |
Borderline Ovarian Mucinous Tumor|Ovarian Mucinous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IA Ovarian Cancer AJCC v6 and v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IB Ovarian Cancer AJCC v6 and v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage IC Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7
|
October 12, 2010 | Phase 3 |
NCT00084643 | National Cancer Institute (NCI) |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
May 2004 | Phase 1 |
NCT04517214 | Fudan University|Fudan University Eye and ENT Hospital|Anhui Provincial Hospital|Sir Run Run Shaw Hospital|Hangzhou Cancer Hospital|Ningbo Medical Center Lihuili Hospital|The First People´s Hospital of Changzhou|Cancer Hospital of Chinese Academy of Medical Science, Shenzhen Center|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Nanfang Hospital of Southern Medical University|Shenzhen People´s Hospital|First Affiliated Hospital of Xi´anJiaotong Univerisity|Guangzhou Panyu Central Hospital |
Nasopharyngeal Carcinoma
|
November 1, 2020 | Phase 2 |
NCT01847599 | Centre Jean Perrin |
Metastatic Breast Cancer|Colorectal Cancer
|
September 6, 2011 | Not Applicable |
NCT00357253 | Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
January 2006 | Phase 1 |
NCT02586610 | Osama Rahma, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme LLC |
Rectal Cancer|Rectal Neoplasm
|
October 2016 | Phase 2 |
NCT00266279 | University of Louisville|James Graham Brown Cancer Center |
Head or Neck Cancer
|
April 2005 | Phase 2 |
NCT00142038 | Charite University, Berlin, Germany |
Stomach Neoplasm|Neoplasm Metastasis
|
March 2004 | Phase 2 |
NCT05429684 | First Affiliated Hospital Xi´an Jiaotong University |
HER2&addition; Breast Cancer
|
January 1, 2021 | Phase 3 |
NCT00434941 | Spanish Breast Cancer Research Group|Hoffmann-La Roche |
Breast Cancer
|
September 2007 | Phase 2 |
NCT01167725 | Walter Reed Army Medical Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2010 | Phase 3 |
NCT01131195 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
July 19, 2010 | Phase 3 |
NCT00418028 | Hospital San Carlos, Madrid|Complexo Hospitalario Universitario de A Coruña |
Metastatic Breast Cancer
|
September 2005 | Phase 2|Phase 3 |
NCT03038217 | Peking Union Medical College Hospital|Geneplus-Beijing Co. Ltd. |
Rectal Cancer, Adenocarcinoma|Neoadjuvant Chemoradiation
|
February 2017 | Phase 3 |
NCT00408564 | Medical University of South Carolina |
Pancreatic Cancer
|
January 2006 | Phase 2 |
NCT00674167 | National University Hospital, Singapore |
Gastric Cancer
|
May 2007 | Phase 2 |
NCT00869050 | Columbia University |
Neuroendocrine Tumors
|
August 2005 | Phase 2 |
NCT03427359 | The University of Hong Kong-Shenzhen Hospital |
Nasopharyngeal Carcinoma
|
January 22, 2015 | Phase 2 |
NCT05136326 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Rectal Cancer
|
December 1, 2021 | Phase 2 |
NCT00048139 | Hoffmann-La Roche |
Colorectal Cancer
|
October 2001 | Phase 2 |
NCT02604615 | The First Affiliated Hospital of Henan University of Science and Technology|The First Affiliated Hospital of Zhengzhou University|Xinyang Central Hospital|Anyang Tumor Hospital|No. 150 Central Hospital of the Chinese People Liberation Army |
Stage III Esophageal Squamous Cell Carcinoma|Esophageal Neoplasms
|
October 2014 | Phase 3 |
NCT01634685 | University of Texas Southwestern Medical Center |
Rectal Adenocarcinoma
|
August 8, 2012 | Phase 1 |
NCT00084617 | National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer
|
March 2004 | Phase 2 |
NCT00438256 | Massachusetts General Hospital|Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Pancreatic Cancer
|
December 2007 | Phase 1|Phase 2 |
NCT00480584 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. |
Metastatic Pancreatic Carcinoma
|
April 2007 | Phase 1 |
NCT00220051 | Royal Marsden NHS Foundation Trust |
Rectal Cancer
|
November 2001 | Phase 2 |
NCT00125021 | Dana-Farber Cancer Institute|Genentech, Inc.|Roche Global Development|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center |
Pancreatic Cancer|Neoplasm Metastasis
|
October 2003 | Phase 2 |
NCT01128842 | Puma Biotechnology, Inc. |
Advanced Malignant Solid Tumors
|
April 2010 | Phase 1 |
NCT05390476 | wang shusen|Sun Yat-sen University |
Triple Negative Breast Cancer
|
August 1, 2022 | Phase 2 |
NCT01640665 | Yale University|Bayer |
Metastatic Breast Cancer|Gastrointestinal Tumors
|
July 2012 | Phase 1 |
NCT00176735 | University of Michigan Rogel Cancer Center |
Pancreatic Cancer
|
December 2001 | Not Applicable |
NCT01844076 | Fox Chase Cancer Center |
Colorectal Adenocarcinoma
|
January 14, 2016 | Phase 1|Phase 2 |
NCT00084591 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
December 2003 | Phase 1 |
NCT00107315 | Roswell Park Cancer Institute |
Colorectal Cancer
|
July 2004 | Phase 2 |
NCT03839823 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
February 25, 2019 | Phase 2 |
NCT02177552 | Rigshospitalet, Denmark |
Esophageal Neoplasms|Stomach Neoplasms
|
June 2014 | Phase 2 |
NCT00201435 | Norwegian Breast Cancer Group |
Breast Neoplasm
|
March 2005 | Phase 2|Phase 3 |
NCT00845910 | Hoffmann-La Roche |
Breast Cancer
|
May 2009 | Phase 2 |
NCT00220129 | Royal Marsden NHS Foundation Trust |
Oesophageal Carcinoma
|
November 2002 | Phase 2 |
NCT00345761 | Chugai Pharmaceutical|Yakult Honsha Co., LTD |
Colorectal Cancer
|
February 2006 | Phase 1|Phase 2 |
NCT04808323 | Medical College of Wisconsin |
Rectal Adenocarcinoma
|
June 17, 2021 | Phase 1 |
NCT01079702 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Advanced Malignancies
|
April 2008 | Phase 1|Phase 2 |
NCT03080805 | Jiangsu HengRui Medicine Co., Ltd. |
HER2 Positive Metastatic Breast Cancer
|
May 3, 2017 | Phase 3 |
NCT03609489 | First Affiliated Hospital of Guangxi Medical University |
Biliary Carcinoma
|
September 10, 2018 | Phase 2 |
NCT02022852 | Harbin Medical University |
Rectal Cancer
|
July 2013 | Phase 2 |
NCT04164199 | BeiGene |
Advanced Malignancies
|
December 19, 2019 | Phase 3 |
NCT00909987 | Grupo Espanol Multidisciplinario del Cancer Digestivo|Royal Marsden NHS Foundation Trust |
Rectum Cancer
|
March 2009 | Phase 2 |
NCT01997333 | Celldex Therapeutics |
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
|
November 2013 | Phase 2 |
NCT01213238 | M.D. Anderson Cancer Center |
Advanced Cancers
|
September 30, 2010 | Phase 1 |
NCT03775928 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Triple-negative Breast Cancer
|
December 18, 2018 | Phase 2 |
NCT04065282 | First Affiliated Hospital of Zhejiang University |
Gastric Cancer
|
August 6, 2019 | Phase 2 |
NCT00440622 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
April 2003 | Phase 3 |
NCT03146377 | The University of Hong Kong |
Colorectal Cancer
|
April 2014 | Phase 2 |
NCT00305877 | National Cancer Institute (NCI) |
Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer
|
February 2006 | Phase 2 |
NCT03322215 | Theodoros Foukakis|Karolinska University Hospital |
Breast Cancer Metastatic
|
October 24, 2017 | Phase 2 |
NCT00470184 | Roswell Park Cancer Institute|National Comprehensive Cancer Network |
Esophageal Cancer
|
November 2006 | Phase 2 |
NCT03921684 | Baruch Brenner|Bristol-Myers Squibb|Rabin Medical Center |
Rectal Cancer
|
April 2019 | Phase 2 |
NCT03607656 | Shanghai University of Traditional Chinese Medicine|RenJi Hospital|Jiangsu Province Hospital of Traditional Chinese Medicine |
Gastric Cancer Stage IIIB|Gastric Cancer Stage IIIC
|
June 8, 2018 | Phase 2|Phase 3 |
NCT00354887 | M.D. Anderson Cancer Center|Sanofi-Synthelabo |
Gastrointestinal Cancer
|
November 2004 | Phase 2 |
NCT02248571 | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Novartis Pharmaceuticals |
Breast Cancer Recurrent|HER2+Neu-negative Carcinoma of Breast|Hormone Receptor Positive Malignant Neoplasm of Breast
|
August 2014 | Phase 4 |
NCT04997837 | Fudan University |
Gastric Cancer
|
July 21, 2021 | Phase 3 |
NCT04310176 | National Cancer Institute, Naples |
Ras-mutated Metastatic Colorectal Cancer
|
May 24, 2019 | Phase 2 |
NCT01641458 | Cantonal Hospital of St. Gallen|University of Bern |
Colorectal Cancer
|
October 2012 | Phase 4 |
NCT02597868 | Zhejiang Cancer Hospital|307 Hospital of PLA|Fudan University|The Tumor Hospital of Jiangsu Province|Fujian Province Tumor Hospital|Zhejiang University|Sir Run Run Shaw Hospital|Zhejiang Chinese Medical University|Hangzhou Cancer Hospital|Jiangsu Provincial People´s Hospital |
Breast Cancer
|
January 2013 | Not Applicable |
NCT02915172 | M.D. Anderson Cancer Center|Eisai Inc. |
Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract
|
December 2016 | Phase 1 |
NCT02218164 | H. Lee Moffitt Cancer Center and Research Institute |
Squamous Cell Carcinoma of Skin|Carcinoma, Squamous Cell
|
August 12, 2014 | Phase 2 |
NCT00814619 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
November 2008 | Phase 2 |
NCT04097444 | Chugai Pharmaceutical |
Metastatic Colorectal Cancer
|
October 11, 2019 | Phase 2 |
NCT00547547 | City of Hope Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 2006 | Phase 1 |
NCT00379262 | Hong Kong Nasopharyngeal Cancer Study Group Limited|The Hong Kong Anti-Cancer Society|hong Kong Cancer Fund |
Nasopharyngeal Carcinoma
|
September 2006 | Phase 3 |
NCT00258310 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 2003 | Phase 2 |
NCT01918644 | University of Wisconsin, Madison |
Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer
|
April 8, 2014 | Phase 1 |
NCT03653507 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
|
November 28, 2018 | Phase 3 |
NCT04894643 | EBG MedAustron GmbH|Landesklinkum Wiener Neustadt |
Pancreatic Cancer|Proton Therapy
|
September 14, 2020 | Not Applicable |
NCT00496301 | Spanish Oncology Genito-Urinary Group |
Carcinoma, Renal Cell
|
November 2006 | Phase 2 |
NCT01268943 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Rectal Neoplasms
|
November 2010 | Phase 1 |
NCT05063786 | Spanish Breast Cancer Research Group|ETOP IBCSG Partners Foundation|Breast International Group|Novartis Pharmaceuticals |
Advanced Breast Cancer
|
September 14, 2021 | Phase 3 |
NCT04404491 | The First Affiliated Hospital of Henan University of Science and Technology |
Esophageal Malignant Neoplasm, Local Recurrence
|
June 1, 2020 | Phase 3 |
NCT01516944 | Hebei Medical University |
Gastric Cancer
|
February 2012 | Phase 2|Phase 3 |
NCT00977379 | Hoffmann-La Roche |
Breast Cancer
|
August 2009 | Phase 2 |
NCT00502671 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2007 | Phase 4 |
NCT00324610 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
Breast Neoplasms|Chemotherapy
|
March 2006 | Phase 1|Phase 2 |
NCT02767661 | Sun Yat-sen University |
Breast Cancer
|
July 19, 2017 | Phase 3 |
NCT04072107 | Sun Yat-sen University|National Cancer Centre, Singapore|Wuzhou Red Cross Hospital|First People´s Hospital of Foshan |
Nasopharyngeal Carcinoma
|
June 1, 2020 | Phase 2 |
NCT04501523 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Triple-negative Breast Cancer
|
August 3, 2020 | Phase 2 |
NCT03770689 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Locally Advanced Rectal Cancer
|
March 20, 2019 | Phase 1|Phase 2 |
NCT01354522 | Peking Union Medical College Hospital |
Breast Cancer
|
May 2011 | Phase 3 |
NCT00848783 | NYU Langone Health |
Gastric Cancer|Gastric Adenocarcinoma|Esophageal Cancer
|
May 2008 | Phase 2 |
NCT01461057 | Hoffmann-La Roche |
Gastric Cancer
|
December 6, 2011 | Phase 2 |
NCT02514278 | University Hospital, Bordeaux |
Rectal Cancer
|
January 28, 2016 | Phase 3 |
NCT00216424 | James A. Haley Veterans Administration Hospital|Hoffmann-La Roche |
Colorectal Cancer
|
February 2005 | Phase 4 |
NCT00078572 | GlaxoSmithKline |
Breast Cancer
|
March 2004 | Phase 3 |
NCT01123473 | European Organisation for Research and Treatment of Cancer - EORTC |
Adenocarcinoma of the Gastroesophageal Junction|Gastric Cancer
|
December 2010 | Phase 2 |
NCT01195298 | South Eastern European Research Oncology Group|Roche Pharma AG |
Breast Cancer|Metastasis
|
May 2010 | Phase 2 |
NCT02076594 | Gruppo Italiano per lo studio dei Carcinomi dell´Apparato Digerente|Regione Lombardia |
Locally Advanced Unresectable Gastric Cancer|Metastatic Gastric Cancer
|
January 2013 | Phase 3 |
NCT05044117 | Sun Yat-sen University|Fujian Medical University Union Hospital|Guangzhou Panyu Central Hospital|The Central Hospital of Yongzhou|The First People´s Hospital of Huaihua|Hanzhong Central Hospital|Yichang Central People´s Hospital|The Affiliated Hospital of Guangdong Medical College|Jiangmen Central Hospital|Xiang Yang No.1 Peoples Hospital |
Head and Neck Squamous Cell Carcinoma
|
October 18, 2021 | Phase 3 |
NCT00345059 | National Cancer Institute, Naples |
Advanced Non-Small Cell Lung Cancer
|
May 2005 | Phase 3 |
NCT00881621 | Georgetown University|GlaxoSmithKline |
Pancreas Cancer
|
August 2009 | Phase 2 |
NCT00159432 | University of Southern California|Hoffmann-La Roche|Genentech, Inc. |
Colorectal Cancer
|
February 2005 | Phase 2 |
NCT00124566 | Eisai Inc. |
Prostate Cancer
|
June 2004 | Phase 2 |
NCT03802591 | CStone Pharmaceuticals |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
March 28, 2019 | Phase 3 |
NCT05201859 | Sun Yat-sen University |
Nasopharyngeal Carcinoma
|
March 29, 2022 | Phase 2 |
NCT01869192 | University of Colorado, Denver |
Malignant Neoplasm of Female Breast
|
March 5, 2003 | Phase 2 |
NCT00789958 | Southwest Oncology Group|National Cancer Institute (NCI) |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer
|
December 2008 | Phase 2 |
NCT04420871 | The Affiliated Hospital of Qingdao University |
Patient Participation
|
December 10, 2018 | Phase 1 |
NCT05052437 | Beijing Biostar Technologies, Ltd|Chengdu Biostar Pharmaceuticals, Ltd |
Advanced and Metastatic Breast Cancer
|
October 22, 2020 | Phase 1 |
NCT00700570 | Hoffmann-La Roche |
Colorectal Cancer
|
August 2008 | Phase 2 |
NCT05227131 | MedSIR|MacroGenics|Seagen Inc. |
Metastatic Breast Cancer|Advanced Breast Cancer|HER2-positive Breast Cancer
|
May 15, 2022 | Phase 2 |
NCT00338988 | M.D. Anderson Cancer Center|Sanofi-Synthelabo |
Cancer of the Gallbladder|Cancer of the Biliary Tract
|
August 2003 | Phase 2 |
NCT02940925 | Sun Yat-sen University |
Nasopharyngeal Carcinoma
|
September 2016 | Phase 3 |
NCT02170090 | Universitätsklinikum Hamburg-Eppendorf|Deutsche Krebshilfe e.V., Bonn (Germany)|Cancer Research UK|Australasian Gastro-Intestinal Trials Group|Dutch Cancer Society |
Cholangiocarcinoma|Gall Bladder Carcinoma
|
April 2014 | Phase 3 |
NCT01158274 | National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-cell Lymphoma|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|HER2-negative Breast Cancer|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Male Breast Cancer|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Colon Cancer|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage III Rectal Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Stage IV Rectal Cancer|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia
|
June 2010 | Phase 1 |
NCT01588990 | Hoffmann-La Roche |
Colorectal Neoplasms
|
June 26, 2012 | Phase 4 |
NCT01494662 | Dana-Farber Cancer Institute|Translational Breast Cancer Research Consortium|Puma Biotechnology, Inc. |
Breast Cancer
|
February 2012 | Phase 2 |
NCT05512520 | Sun Yat-sen University |
Metastatic Esophageal Squamous Cell Carcinoma
|
September 20, 2022 | Phase 2 |
NCT04389073 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Huanxing Cancer Hospital |
Metastatic Breast Cancer
|
April 1, 2020 | Phase 2 |
NCT05415917 | Rutgers, The State University of New Jersey |
Pancreatic Cancer
|
July 29, 2022 | Phase 2 |
NCT00678535 | Merck KGaA, Darmstadt, Germany |
Gastric Cancer
|
June 2008 | Phase 3 |
NCT04276493 | BeiGene |
Breast Cancer|Gastric Cancer|Gastroesophageal Junction Cancer
|
March 26, 2020 | Phase 1|Phase 2 |
NCT00042965 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Kidney Cancer
|
October 2002 | Phase 2 |
NCT01048580 | AEterna Zentaris|SCRI Development Innovations, LLC |
Colon Cancer
|
October 2009 | Phase 1 |
NCT01630083 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction|CLDN18.2-positive Adenocarcinoma of Esophagus|CLDN18.2-positive Gastric Adenocarcinoma
|
July 19, 2012 | Phase 2 |
NCT01572324 | Peking University |
Biliary Tract Cancer
|
March 2012 | Phase 2 |
NCT04582968 | Fudan University |
Breast Cancer|Brain Metastases|HER2-positive Breast Cancer
|
September 1, 2019 | Phase 1|Phase 2 |
NCT00191438 | Eli Lilly and Company |
Breast Neoplasms
|
October 2002 | Phase 3 |
NCT04428151 | Merck Sharp & Dohme LLC|Eisai Inc. |
Squamous Cell Carcinoma of Head and Neck
|
August 6, 2020 | Phase 2 |
NCT00779454 | Vejle Hospital |
Cholangiocarcinoma
|
September 2008 | Phase 2 |
NCT00196820 | German Breast Group|Hoffmann-La Roche |
Breast Cancer
|
July 2005 | Phase 2 |
NCT00019773 | National Cancer Institute (NCI) |
Carcinoma of the Appendix|Colorectal Cancer|Small Intestine Cancer
|
July 1999 | Phase 1 |
NCT02864849 | Peking University Cancer Hospital & Institute |
Rectal Cancer
|
August 2016 | Phase 2 |
NCT01238029 | Sponsor GmbH|iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Arbeitskreis Klinische Studien|GlaxoSmithKline |
Metastatic Breast Cancer|HER2 Positive|First or Second Line Therapy|Failure or Contraindication of Trastuzumab Therapy
|
October 2010 | Phase 1 |
NCT00354224 | Medical University of South Carolina |
Gastric Cancer
|
January 2005 | Phase 2 |
NCT03889626 | Fudan University |
Stomach Neoplasms|Gastrointestinal Neoplasms|Stomach Diseases|Digestive System Neoplasms|Capecitabine|Apatinib|Neoplasms|Molecular Mechanisms of Pharmacological Action
|
March 22, 2019 | Phase 3 |
NCT00623805 | Hoffmann-La Roche |
Colorectal Cancer
|
March 2008 | Phase 3 |
NCT00068588 | National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
October 2003 | Phase 2 |
NCT02505750 | Centre Antoine Lacassagne|Centre de Haute Energie|Centre Azuréen de Cancérologie|Hôpital de la Croix-Rousse|Institut Paoli-Calmettes|Hôpital de la Timone|Centre de radiothérapie Bayard|Centre Oncologie Radiothérapie de Mâcon|Centre Leon Berard|Hospices Civils de Lyon|Clinique Charcot|Institut de Cancérologie Lucien Neuwirth|The Clatterbridge Cancer Centre NHS Foundation Trust|Spire Hull and East Riding Hospital|Nottingham University Hospitals NHS Trust|Royal Surrey County Hospital NHS Foundation Trust|Uppsala University Hospital|Karolinska Institutet|Aarhus University Hospital |
Rectal Neoplasms
|
June 24, 2015 | Phase 3 |
NCT01710592 | Cancer Trials Ireland |
Gastro Oesophageal Cancer
|
May 2007 | Phase 2 |
NCT00811993 | Hoffmann-La Roche |
Neoplasms
|
February 2009 | Phase 1 |
NCT00442637 | Dutch Colorectal Cancer Group|Koningin Wilhelmina Fonds|Sanofi|Hoffmann-La Roche |
Colorectal Cancer Metastatic
|
January 2007 | Phase 3 |
NCT00538291 | City of Hope Medical Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2005 | Phase 2 |
NCT02669173 | Case Comprehensive Cancer Center |
Glioblastoma
|
October 11, 2016 | Phase 1 |
NCT02735239 | Ludwig Institute for Cancer Research|AstraZeneca |
Esophageal Cancer
|
June 24, 2016 | Phase 1|Phase 2 |
NCT00156975 | Arbeitsgruppe Lebermetastasen und Tumoren |
Colorectal Neoplasms|Liver Metastases
|
November 2004 | Phase 3 |
NCT03082053 | Aslan Pharmaceuticals |
Advanced or Metastatic Biliary Tract Cancer|Advanced or Metastatic Solid Tumors
|
January 31, 2017 | Phase 1 |
NCT04963088 | The First Affiliated Hospital with Nanjing Medical University |
Gastric Cancer
|
March 6, 2021 | Phase 1|Phase 2 |
NCT02494583 | Merck Sharp & Dohme LLC |
Gastric Adenocarcinoma
|
July 31, 2015 | Phase 3 |
NCT01941966 | Instituto do Cancer do Estado de São Paulo |
Anal Canal Cancer.
|
November 2010 | Phase 2 |
NCT04639986 | Everest Medicines|Iqvia Pty Ltd|Medidata Solutions|Parexel |
Metastatic Breast Cancer
|
November 23, 2020 | Phase 3 |
NCT00146588 | Craig A. Bunnell, MD, MPH|Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Pharmacia |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
April 2002 | Not Applicable |
NCT00039390 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 2002 | Phase 1 |
NCT03358004 | Mario Negri Institute for Pharmacological Research |
Triple Negative Breast Cancer
|
June 14, 2017 | Phase 2 |
NCT00165217 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Colorectal Adenocarcinoma
|
November 2001 | Phase 2 |
NCT02954055 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
September 13, 2017 | Phase 2 |
NCT05131893 | National Institute of Oncology, Hungary |
Breast Cancer
|
March 2022 | |
NCT01880658 | Sun Yat-sen University |
Colorectal Neoplasms
|
June 2013 | Phase 2 |
NCT01671891 | Fudan University |
Rectal Cancer
|
February 2012 | |
NCT00382720 | Sanofi |
Stomach Neoplasms
|
September 2006 | Phase 2 |
NCT03487666 | Georgetown University|Bristol-Myers Squibb |
Triple Negative Breast Cancer
|
May 21, 2018 | Phase 2 |
NCT00203411 | Translational Oncology Research International|Genentech, Inc. |
Colorectal Cancer
|
March 2006 | Phase 2 |
NCT02352831 | Washington University School of Medicine |
Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer
|
August 31, 2015 | Phase 1|Phase 2 |
NCT02958111 | Sun Yat-sen University|Tongji Hospital|Wuhan Union Hospital, China|Peking University|Air Force Military Medical University, China|Second Affiliated Hospital of Soochow University|West China Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical University|First People´s Hospital of Foshan|Fifth Affiliated Hospital, Sun Yat-Sen University|Cancer Hospital of Guizhou Province|Xiangya Hospital of Central South University|First Affiliated Hospital of Zhejiang University|Jilin Provincial Tumor Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|The First Affiliated Hospital of Xiamen University|Cancer Hospital of Guangxi Medical University |
Nasopharyngeal Carcinoma
|
January 2017 | Phase 3 |
NCT03387592 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Neuroendocrine Carcinoma
|
March 6, 2017 | Phase 2 |
NCT01060007 | Washington University School of Medicine |
Rectal Neoplasms
|
November 2009 | Phase 2 |
NCT04159142 | Hebei Medical University Fourth Hospital|Beijing 302 Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. |
Triple Negative Breast Cancer|Nab-paclitaxel
|
November 20, 2019 | Phase 2 |
NCT00049660 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
September 2002 | Phase 2|Phase 3 |
NCT01471847 | Novartis Pharmaceuticals|Novartis |
Locally Advance Breast Cancer (LABC)|Metastatic Breast Cancer (MBC)
|
February 2012 | Phase 1 |
NCT00383695 | Royal Marsden NHS Foundation Trust |
Colorectal Cancer
|
September 2005 | Phase 2 |
NCT01396668 | Seoul National University Hospital |
Pancreatic Cancer
|
December 2004 | Phase 2 |
NCT03775525 | Genzada Pharmaceuticals USA, Inc.|Translational Drug Development |
Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach|Lymphoma|Sarcoma|Cutaneous T Cell Lymphoma|Head and Neck Squamous Cell Carcinoma|Basal Cell Carcinoma|Cutaneous T-cell Lymphoma|Cutaneous Squamous Cell Carcinoma
|
March 1, 2019 | Phase 1 |
NCT00909402 | Bristol-Myers Squibb|Exelixis |
Stomach Neoplasms|Esophageal Neoplasms
|
November 2009 | Phase 1 |
NCT02935309 | H. Lee Moffitt Cancer Center and Research Institute |
Rectal Cancer|Rectal Adenocarcinoma
|
October 14, 2016 | Phase 1 |
NCT00169000 | Dartmouth-Hitchcock Medical Center|Hoffmann-La Roche |
Metastatic Breast Cancer
|
January 2003 | Phase 1 |
NCT01423604 | Incyte Corporation |
Pancreatic Cancer
|
July 2011 | Phase 2 |
NCT03399110 | Fudan University |
Gastric Cancer
|
December 1, 2017 | Phase 3 |
NCT02473094 | University of Campinas, Brazil |
Rectal Neoplasms|Adenocarcinoma|Carcinoma
|
July 2015 | Phase 2 |
NCT00885066 | Centre Antoine Lacassagne |
Pancreatic Cancer
|
May 2008 | Phase 1 |
NCT02115152 | Guangxi Medical University |
Stage II Breast Cancer|Stage III Breast Cancer
|
June 2014 | Phase 2 |
NCT00657137 | Tragara Pharmaceuticals, Inc. |
Breast Cancer
|
April 2008 | Phase 2 |
NCT02861300 | David Bajor|Case Comprehensive Cancer Center |
Colorectal Cancer|Colon Cancer|Rectal Cancer|Solid Tumor
|
September 12, 2016 | Phase 1|Phase 2 |
NCT01130805 | Samsung Medical Center |
Gastric Cancer
|
December 2010 | Phase 2 |
NCT00006108 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 1|Phase 2 |
NCT01517009 | Jeroen Bosch Ziekenhuis|Eindhoven Cancer Registry |
Gastric Cancer
|
June 2008 | Phase 2 |
NCT01941641 | Chinese University of Hong Kong |
Rectal Cancer
|
October 9, 2013 | Phase 2 |
NCT00121134 | Harold J. Burstein, MD, PhD|Genentech, Inc.|Beth Israel Deaconess Medical Center|Indiana University School of Medicine|University of California, San Francisco|University of North Carolina|Dana-Farber Cancer Institute |
Breast Cancer
|
June 2005 | Not Applicable |
NCT01196455 | Croatian Cooperative Group for Clinical Research in Oncology|Roche Pharma AG |
Breast Cancer|Metastasis
|
March 2006 | Phase 2 |
NCT01836432 | NewLink Genetics Corporation|Lumos Pharma |
Pancreatic Cancer|Pancreatic Carcinoma Non-resectable|Locally Advanced Malignant Neoplasm
|
May 2013 | Phase 3 |
NCT00100815 | Roswell Park Cancer Institute |
Pancreatic Cancer
|
August 2004 | Phase 2 |
NCT00123851 | Dana-Farber Cancer Institute|Sanofi-Synthelabo|OSI Pharmaceuticals|Hoffmann-La Roche|Genentech, Inc.|Massachusetts General Hospital|Beth Israel Deaconess Medical Center |
Colorectal Cancer|Neoplasm Metastasis
|
March 2003 | Phase 2 |
NCT04250948 | Sun Yat-sen University|Shanghai Junshi Bioscience Co., Ltd. |
Gastric Cancer|Locally Advanced Solid Tumor
|
October 12, 2019 | Phase 2 |
NCT00868998 | Columbia University |
Biliary Cancer
|
August 2005 | Phase 2 |
NCT00033540 | Southwest Oncology Group|National Cancer Institute (NCI) |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer
|
September 2003 | Phase 2 |
NCT01268384 | Asan Medical Center |
Pancreatic Cancer
|
April 2006 | Phase 2 |
NCT04782804 | Fudan University |
Cholangiocarcinoma, Intrahepatic
|
January 1, 2021 | Phase 1|Phase 2 |
NCT01161186 | University of California, San Francisco|Celgene Corporation |
Pancreatic Neoplasms|Pancreatic Cancer|Adenocarcinoma
|
July 2010 | Phase 1 |
NCT02460419 | Sun Yat-sen University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Affiliated Cancer Hospital of Shantou University Medical College |
Nasopharyngeal Carcinoma
|
April 2015 | Phase 3 |
NCT00022698 | Hoffmann-La Roche |
Colorectal Cancer
|
May 2001 | Phase 2 |
NCT05314998 | John Neoptolemos|Molecular Health GmbH|Deutsches Krebsforschungszentrum (DKFZ)|Nationales Centrum für Tumorerkrankungen|Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Institut für Medizinische Biometrie|Heidelberg University |
Pancreatic Ductal Adenocarcinoma
|
November 1, 2022 | Phase 3 |
NCT00155259 | National Taiwan University Hospital |
Breast Cancer
|
October 2004 | Phase 2 |
NCT02780700 | Boehringer Ingelheim |
Colorectal Neoplasms
|
July 5, 2016 | Phase 2 |
NCT01007552 | Roswell Park Cancer Institute|Genentech, Inc. |
Cholangiocarcinoma
|
December 2009 | Phase 2 |
NCT04844385 | Sun Yat-sen University |
Esophageal Squamous Cell Carcinoma
|
February 20, 2021 | Phase 2 |
NCT00959946 | Pfizer |
Advanced Breast Cancer (Parts 1 and 2)|Advanced Pancreatic Cancer (Part 1)|Advanced Colorectal Cancer (Part 1)|Advanced Cholangiocarcinoma (Part 1)|Advanced Glioblastoma Multiforme (Part 1)
|
September 2009 | Phase 1|Phase 2 |
NCT00675012 | AGC Biologics S.p.A. |
Colon Cancer
|
December 2007 | Phase 2 |
NCT05494190 | Eye & ENT Hospital of Fudan University|Shandong Provincial Hospital|Harbin Medical University Third Affiliated Hospital |
Hypopharyngeal Carcinoma
|
October 2022 | Not Applicable |
NCT00069121 | Hoffmann-La Roche |
Colorectal Cancer
|
April 18, 2003 | Phase 3 |
NCT05236972 | Sun Yat-sen University|Second Affiliated Hospital, School of Medicine, Zhejiang University|West China Hospital |
Colorectal Carcinoma
|
January 1, 2022 | Phase 3 |
NCT04185649 | Bio-Thera Solutions |
HER2-positive Advanced Breast Cancer
|
July 1, 2018 | Phase 3 |
NCT05009069 | Hoffmann-La Roche |
Rectal Neoplasms|Rectal Cancer
|
March 18, 2022 | Phase 2 |
NCT02919878 | King Faisal Specialist Hospital & Research Center |
Rectal Adenocarcinoma
|
December 2014 | Phase 2 |
NCT01924819 | Australasian Gastro-Intestinal Trials Group|National Health and Medical Research Council, Australia|Trans Tasman Radiation Oncology Group|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group |
Gastric Cancer
|
September 2009 | Phase 2|Phase 3 |
NCT00309556 | Austrian Breast & Colorectal Cancer Study Group|Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi |
Breast Cancer
|
February 2005 | Phase 3 |
NCT01191697 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Genentech, Inc. |
Esophageal Cancer|Gastric Cancer
|
February 2011 | Phase 2 |
NCT00214864 | Cancer Research Network|Hoffmann-La Roche |
Metastatic Breast Cancer
|
December 2002 | Phase 2 |
NCT00156312 | University of Michigan Rogel Cancer Center |
Breast Cancer
|
July 2003 | Not Applicable |
NCT03515941 | Tannaz Armaghany|Baylor College of Medicine |
Gastrointestinal Cancer
|
June 22, 2018 | Early Phase 1 |
NCT01203306 | University of Turin, Italy |
Neuroendocrine Carcinomas
|
January 2006 | Phase 2 |
NCT00048126 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2001 | Phase 2 |
NCT00215644 | Merck KGaA, Darmstadt, Germany |
Esophageal Cancer|Gastric Cancer
|
August 31, 2005 | Phase 2 |
NCT00003704 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Cancer
|
April 1999 | Phase 1 |
NCT03231176 | Aslan Pharmaceuticals |
Biliary Tract Cancer
|
December 19, 2017 | Phase 2 |
NCT00215982 | H. Lee Moffitt Cancer Center and Research Institute|Roche Pharma AG |
Colorectal Cancer
|
December 2004 | Phase 2 |
NCT04301557 | Sun Yat-sen University |
DMMR Colorectal Cancer|MSI-H Colorectal Cancer|Locally Advanced Colorectal Cancer
|
July 31, 2020 | Phase 2 |
NCT01924078 | Fudan University |
Breast Cancer
|
October 2010 | Phase 2 |
NCT02395640 | Fudan University |
Gastric Cancer
|
March 2015 | Phase 3 |
NCT02794571 | Genentech, Inc. |
Advanced+Metastatic Tumors
|
May 23, 2016 | Phase 1 |
NCT01151761 | Stanford University |
Cholangiocarcinoma|Hepatobiliary Neoplasm|Liver Cancer|Bile Duct Cancer|Cancer of Gallbladder
|
January 2011 | Phase 2 |
NCT00669370 | University of Turku|Sanofi |
Stomach Neoplasms
|
June 2006 | Phase 2 |
NCT02558959 | Zhejiang University |
Biliary Tract Neoplasms
|
September 1, 2015 | Phase 2 |
NCT05321329 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Pseudomyxoma Peritonei
|
December 3, 2018 | Phase 2 |
NCT01962246 | Hebei Medical University |
Gastroesophageal Junction Adenocarcinoma
|
February 2012 | Phase 2|Phase 3 |
NCT02119663 | Incyte Corporation |
Pancreatic Cancer
|
June 2014 | Phase 3 |
NCT04080843 | Zhejiang University|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Colorectal Cancer|RAS and BRAF Wild-type|Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Rectal Diseases
|
November 15, 2019 | Phase 2 |
NCT00216086 | Gabi Chiorean, MD|Pfizer|Roche Pharma AG|Walther Cancer Institute|Hoosier Cancer Research Network |
Rectal Cancer
|
May 2005 | Phase 2 |
NCT03093870 | Aslan Pharmaceuticals|bioRASI, LLC|CMIC Co, Ltd. Japan|Syneos Health |
Biliary Tract Cancer
|
July 4, 2017 | Phase 2|Phase 3 |
NCT02338245 | Aslan Pharmaceuticals |
Metastatic Breast Cancer
|
December 29, 2014 | Phase 2 |
NCT00089479 | Hoffmann-La Roche |
Breast Cancer
|
August 2002 | Phase 3 |
NCT03500380 | RemeGen Co., Ltd. |
Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma|HER2-positive Advanced Breast With Liver Metastases
|
April 24, 2018 | Phase 2|Phase 3 |
NCT02121405 | Zhejiang University |
Colorectal Neoplasm|Effects of Radiation Therapy|Effects of Chemotherapy|Surgery
|
October 2015 | Phase 3 |
NCT04849364 | Bryan Schneider, MD|Genentech, Inc.|Pfizer|Foundation Medicine|Indiana University|Epic Sciences|Vera Bradley Foundation for Breast Cancer Research|Hoosier Cancer Research Network |
Breast Cancer|Triple Negative Breast Cancer
|
August 24, 2021 | Phase 2 |
NCT00353262 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2005 | Phase 1 |
NCT03817268 | The First Affiliated Hospital of Anhui Medical University |
Gastric Cancer
|
January 16, 2019 | Phase 3 |
NCT00430027 | University of Colorado, Denver|Bristol-Myers Squibb|Sanofi |
Esophageal Adenocarcinoma
|
November 2006 | Not Applicable |
NCT02688712 | Providence Health & Services|Eli Lilly and Company |
Rectal Adenocarcinoma
|
March 24, 2016 | Phase 2 |
NCT00148122 | University of Michigan Rogel Cancer Center |
Head and Neck Cancer
|
November 2002 | Phase 2 |
NCT00869258 | Columbia University |
Pancreatic Cancer Stage IVA
|
June 2005 | Phase 2 |
NCT01017822 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Pancreatic Cancer
|
Phase 1|Phase 2 | |
NCT01323530 | Eisai Limited|Eisai Inc. |
Metastatic Breast Cancer
|
January 26, 2010 | Phase 1|Phase 2 |
NCT00390676 | Adherex Technologies, Inc.|US Oncology Research |
Neoplasms
|
November 2006 | Phase 1 |
NCT01308190 | Corporacion Parc Tauli|Fundación Olga Torres |
Rectal Cancer
|
August 2010 | Phase 3 |
NCT03132025 | Yanqiao Zhang|Harbin Medical University |
Metastatic Colorectal Cancer
|
April 30, 2017 | Phase 2 |
NCT04220203 | Seagen Inc.|Parexel |
HER2-positive Breast Cancer
|
||
NCT04337658 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer
|
July 1, 2020 | Phase 3 |
NCT01300962 | UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals |
Metastatic Breast Cancer
|
August 2011 | Phase 1 |
NCT03462251 | iOMEDICO AG|Novartis Pharmaceuticals |
Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer
|
May 24, 2018 | Phase 3 |
NCT02955940 | Incyte Corporation |
Pancreatic Cancer|Colorectal Cancer (CRC)|Breast Cancer|Lung Cancer
|
November 30, 2016 | Phase 2 |
NCT01234402 | Eli Lilly and Company |
Breast Cancer
|
March 2011 | Phase 2 |
NCT05093907 | BeyondBio Inc. |
Metastatic Colorectal Cancer
|
August 31, 2021 | Phase 1|Phase 2 |
NCT03507465 | Guangdong Provincial People´s Hospital |
Breast Cancer
|
November 29, 2017 | Phase 2|Phase 3 |
NCT00634725 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Pancreatic Cancer
|
February 2008 | Phase 3 |
NCT04245865 | Vejle Hospital |
Colorectal Cancer Metastatic
|
June 26, 2020 | Phase 2 |
NCT04494425 | AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo |
Advanced or Metastatic Breast Cancer
|
July 24, 2020 | Phase 3 |
NCT03469557 | BeiGene |
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
|
July 18, 2017 | Phase 2 |
NCT04495088 | Ralf Hofheinz|Deutsche Krebshilfe e.V., Bonn (Germany)|Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|German Rectal Cancer Study Group|Universitätsmedizin Mannheim |
Rectal Cancer
|
September 30, 2020 | Phase 3 |
NCT02846428 | Hoffmann-La Roche |
Breast Cancer
|
March 2004 | Phase 2 |
NCT00114231 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Colorectal Cancer
|
May 2006 | Phase 2 |
NCT04405206 | Peking University Cancer Hospital & Institute |
Rectum Cancer
|
May 25, 2020 | |
NCT02422199 | Jiangsu HengRui Medicine Co., Ltd. |
HER2 Positive Metastatic Breast Cancer
|
May 2015 | Phase 1|Phase 2 |
NCT00408408 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
November 2006 | Phase 3 |
NCT04227041 | Qingdao Zhixin Health Technology Co., Ltd.|The Affiliated Hospital of Qingdao University |
HER-2 Positive Colorectal Cancer
|
January 10, 2020 | Phase 1|Phase 2 |
NCT00005649 | Hoffmann-La Roche |
Breast Cancer
|
July 1998 | Phase 2 |
NCT04661150 | Hoffmann-La Roche |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
March 12, 2021 | Phase 2 |
NCT04296240 | Peking University Cancer Hospital & Institute |
Rectal Cancer
|
March 1, 2019 | Phase 2 |
NCT01939054 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Biotech Pharmaceutical Co., Ltd. |
Breast Cancer
|
September 2013 | Phase 2 |
NCT01132664 | Novartis Pharmaceuticals|Novartis |
Metastatic Breast Cancer|HER2&addition; Breast Cancer
|
May 2010 | Phase 1|Phase 2 |
NCT00585078 | Beth Israel Deaconess Medical Center|Sanofi|Dana-Farber Cancer Institute |
Pancreatic Cancer
|
May 2004 | Phase 2 |
NCT00464295 | Aga Khan University |
Carcinoma, Hepatocellular
|
August 2006 | Phase 2 |
NCT01549795 | Azienda Ospedaliera di Padova |
Hilar Cholangiocarcinoma|Primary Sclerosing Cholangitis
|
January 2012 | Not Applicable |
NCT02024607 | Sumitomo Pharma Oncology, Inc. |
Advanced Gastrointestinal Cancer
|
January 2014 | Phase 1|Phase 2 |
NCT03167164 | ImmunityBio, Inc. |
Merkel Cell Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT01633203 | Grupo Oncologico Cooperativo Chileno de Investigation |
Gastric Cancer
|
August 2010 | |
NCT00191152 | Eli Lilly and Company |
Breast Cancer|Breast Neoplasms|Cancer of the Breast
|
February 2002 | Phase 3 |
NCT00373113 | Pfizer |
Breast Neoplasms
|
November 2006 | Phase 3 |
NCT04135313 | Blokhin´s Russian Cancer Research Center |
Rectal Neoplasms Malignant|Rectum Carcinoma|Rectal Cancer
|
October 20, 2019 | Phase 3 |
NCT05002686 | Ruijin Hospital |
Gastric Cancer
|
August 7, 2021 | Phase 2|Phase 3 |
NCT01131078 | Hoffmann-La Roche |
Colorectal Cancer
|
June 2005 | Phase 2 |
NCT03958721 | A Bapsi Chakravarthy, MD|Vanderbilt-Ingram Cancer Center |
Resistant Breast Cancer|Non-metastatic Invasive Breast Cancer
|
July 18, 2019 | Phase 1 |
NCT01061515 | Washington University School of Medicine |
Carcinoma
|
May 10, 2011 | Phase 1 |
NCT02025036 | The First Affiliated Hospital of Henan University of Science and Technology|Luoyang Central Hospital|Military 150 Hospital|Anyang Cancer Hospital|Nanyang Central Hospital|Henan Oncology Hospital|The First Affiliated Hospital of Xinyang Medical College|Sanmenxia Central Hospital |
Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma
|
October 2014 | Phase 3 |
NCT00433589 | European Organisation for Research and Treatment of Cancer - EORTC|Agendia|Breast International Group|Roche Pharma AG|Novartis|Sanofi |
Breast Cancer
|
February 2007 | Phase 3 |
NCT03377387 | Memorial Sloan Kettering Cancer Center|Puma Biotechnology, Inc. |
Breast Cancer
|
December 13, 2017 | Phase 1|Phase 2 |
NCT03813641 | Shenzhen People´s Hospital |
Colorectal Cancer
|
January 28, 2019 | Phase 2 |
NCT01845337 | University of Edinburgh|NHS Lothian |
Gastrointestinal Cancer|Cancer of Unknown Primary Site|Pancreatic Cancer|Bile Duct Neoplasms
|
February 5, 2014 | Phase 2 |
NCT01891227 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Breast Cancer
|
August 9, 2013 | Phase 2 |
NCT04302441 | Fudan University |
Breast Cancer
|
November 10, 2016 | Phase 2 |
NCT04882241 | Merck Sharp & Dohme LLC |
Gastric Cancer|Gastroesophageal Junction Cancer
|
July 29, 2020 | Phase 3 |
NCT01759238 | Universitätsklinikum Hamburg-Eppendorf |
Colorectal Cancer|Metastases
|
May 2013 | Phase 2 |
NCT00268151 | University of Louisville|James Graham Brown Cancer Center|Sanofi |
Carcinoma, Non-Small Cell Lung
|
February 2005 | Phase 1 |
NCT01349088 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Amgen|Thomas Jefferson University |
Breast Cancer|Metastatic Breast Cancer|Stage IV Breast Cancer
|
December 2013 | Phase 1|Phase 2 |
NCT02119026 | Prof. Dr. Werner Scheithauer|Medical University of Vienna |
Metastatic Colorectal Cancer
|
February 2011 | Phase 2 |
NCT02603159 | The First Affiliated Hospital of Henan University of Science and Technology |
Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma
|
October 2014 | Phase 3 |
NCT05216653 | Sir Run Run Shaw Hospital |
MSS Locally Advanced Rectal Adenocarcinoma
|
April 7, 2022 | Phase 2 |
NCT04566380 | Ono Pharmaceutical Co. Ltd |
Pan-tumor
|
September 10, 2020 | Phase 2 |
NCT00568022 | R-Pharm |
Breast Cancer
|
February 2008 | Phase 1 |
NCT02563054 | Hoffmann-La Roche |
Gastric Cancer
|
April 2003 | Phase 3 |
NCT04769050 | Fudan University |
Breast Cancer
|
February 18, 2021 | |
NCT03853707 | City of Hope Medical Center|National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
|
March 4, 2019 | Phase 1|Phase 2 |
NCT01077986 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Metastatic Pancreatic Cancer
|
August 2009 | Phase 1|Phase 2 |
NCT04679597 | Institute of Oncology Ljubljana |
Rectal Cancer
|
January 1, 2016 | |
NCT00327743 | Sanofi |
Breast Cancer|Cancer
|
August 2006 | Phase 1|Phase 2 |
NCT01044433 | Abramson Cancer Center of the University of Pennsylvania |
Head and Neck Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity
|
October 2009 | Phase 2 |
NCT03916510 | University of Oxford|PsiOxus Therapeutics Ltd|Cancer Research UK |
Locally Advanced Rectal Cancer
|
July 1, 2019 | Phase 1 |
NCT05585814 | Shanghai Changzheng Hospital |
Locally Advanced Colorectal Cancer
|
October 2022 | Phase 2 |
NCT02004769 | Sun Yat-sen University|Fudan University|307 Hospital of PLA|Shandong Tumor Hospital|Tongji Hospital|West China Hospital|Shandong Provincial Hospital|Second Affiliated Hospital of Suzhou University|Tianjin Medical University General Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sixth Affiliated Hospital, Sun Yat-sen University|Nanfang Hospital of Southern Medical University |
Stomach Neoplasms|Neoplasms Metastasis|ERBB2 Gene Amplification
|
November 2013 | Phase 2 |
NCT00483405 | UNC Lineberger Comprehensive Cancer Center|Sanofi|Roche Pharma AG|Bristol-Myers Squibb|National Center for Research Resources (NCRR)|National Cancer Institute (NCI) |
Liver Cancer
|
October 2006 | Phase 2 |
NCT04753879 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme LLC |
Metastatic Pancreatic Cancer
|
September 29, 2021 | Phase 2 |
NCT04034251 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Gastric Adenocarcinoma|Gastric Cancer|Esophagogastric Junction|Peritoneal Carcinomatosis
|
June 9, 2020 | Phase 2 |
NCT00159445 | University of Southern California|Eli Lilly and Company |
Colorectal Cancer|Colon Cancer
|
March 2004 | Phase 2 |
NCT00630890 | University of California, San Francisco |
Cholangiocarcinoma|Klatskin Tumor|Biliary Tract Cancer
|
October 2007 | Phase 1 |
NCT01506167 | Hoffmann-La Roche |
Colorectal Cancer
|
July 6, 2012 | |
NCT05016869 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Metastatic Colorectal Cancer
|
April 12, 2022 | Phase 1|Phase 2 |
NCT01322152 | Fudan University |
Colorectal Cancer
|
March 2011 | Phase 2 |
NCT05163223 | Aston Sci. Inc. |
Breast Cancer
|
February 28, 2022 | Phase 2 |
NCT00082095 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA |
Metastatic Breast Cancer
|
April 2004 | Phase 3 |
NCT02830139 | Wuhan University |
Malignant Neoplasm of Colorectum
|
July 2016 | Phase 2 |
NCT04012918 | Ain Shams University |
Metastatic Breast Cancer
|
August 30, 2018 | Phase 2 |
NCT01718808 | Swiss Group for Clinical Cancer Research |
Metastatic Colorectal Cancer
|
November 2012 | Phase 2 |
NCT03821454 | Zhejiang Cancer Hospital |
Breast Cancer
|
February 1, 2019 | Not Applicable |
NCT03383679 | UNICANCER |
Breast Cancer Female|Triple Negative and Androgen Receptor Positive
|
March 14, 2018 | Phase 2 |
NCT02656589 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Huiping Li,M.D., Ph.D.,Peking University Cancer Hospital |
Breast Cancer
|
June 2015 | |
NCT02253459 | Beijing Biostar Technologies, Ltd |
Breast Cancer
|
August 2014 | Phase 3 |
NCT00408772 | University of California, Davis|Sanofi |
Colorectal Cancer|Metastatic Cancer
|
June 2007 | Phase 2 |
NCT04411537 | Fudan University |
Locally Advanced Rectal Cancer
|
July 1, 2020 | Phase 2 |
NCT00047710 | M.D. Anderson Cancer Center|Genentech, Inc. |
Pancreatic Cancer
|
September 2002 | Phase 1 |
NCT00301925 | Institute of Cancer Research, United Kingdom |
Breast Cancer
|
December 16, 2005 | Phase 3 |
NCT00081224 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Colorectal Cancer
|
December 2004 | Phase 2 |
NCT00842686 | Institute of Oncology Ljubljana |
Locally Advanced Rectal Cancer
|
January 2009 | Phase 2 |
NCT03907475 | National Cancer Institute (NCI) |
Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
June 25, 2019 | Phase 2 |
NCT03300609 | University of Southern California|National Cancer Institute (NCI)|Amgen |
Colorectal Adenocarcinoma|RAS Wild Type|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7
|
February 27, 2018 | Phase 3 |
NCT02250209 | Chinese PLA General Hospital |
Gastric Cancer
|
July 2014 | Phase 2 |
NCT03167177 | ImmunityBio, Inc. |
Melanoma
|
December 2017 | Phase 1|Phase 2 |
NCT02798510 | Fudan University |
Malignant Neoplasm Other Gallbladder+Extrahepatic Bile Duct
|
April 2016 | Phase 3 |
NCT03169790 | ImmunityBio, Inc. |
Non Hodgkin Lymphoma
|
December 2017 | Phase 1|Phase 2 |
NCT01233505 | National Cancer Institute (NCI) |
Adenocarcinoma of the Pancreas|Adenocarcinoma of the Stomach|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Mucinous Cystadenocarcinoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
October 2010 | Phase 1 |
NCT02005549 | Hoffmann-La Roche |
Breast Cancer
|
February 2006 | Phase 2 |
NCT02743221 | Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier |
Metastatic Colorectal Cancer
|
April 29, 2016 | Phase 2 |
NCT04895358 | Merck Sharp & Dohme LLC |
Breast Neoplasms
|
June 18, 2021 | Phase 3 |
NCT00985556 | Yonsei University|National Cancer Institute (NCI) |
Gastric Cancer
|
January 2009 | Phase 2 |
NCT01386346 | Weill Medical College of Cornell University|Celgene Corporation |
Esophageal Cancer|Malignant Neoplasm of Cardio-esophageal Junction of Stomach
|
June 2011 | Phase 1 |
NCT00574171 | University of Wisconsin, Madison|GlaxoSmithKline |
Metastatic Colorectal Cancer
|
September 2007 | Phase 2 |
NCT05064085 | H. Lee Moffitt Cancer Center and Research Institute|Regeneron Pharmaceuticals |
Hormone Receptor-positive Breast Cancer
|
October 12, 2021 | Phase 1 |
NCT03792269 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Colorectal Cancer Metastatic|Chemotherapy Effect|Chemotherapeutic Toxicity
|
January 1, 2016 | Phase 2 |
NCT03638648 | Zhejiang Cancer Hospital |
Breast Cancer
|
November 1, 2019 | Phase 2 |
NCT00122291 | Alberta Health services|AHS Cancer Control Alberta |
Rectal Cancer|Neoplasm Metastasis
|
January 2002 | Phase 2 |
NCT00054457 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
September 2003 | Phase 2 |
NCT00484939 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2007 | Phase 3 |
NCT02838238 | Peking Union Medical College Hospital |
Breast Cancer
|
January 2014 | Phase 2 |
NCT05247905 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Metastatic Pancreatic Neuroendocrine Tumor|Unresectable Pancreatic Neuroendocrine Carcinoma
|
March 16, 2022 | Phase 2 |
NCT00226941 | George Albert Fisher|Bristol-Myers Squibb|Stanford University |
Rectal Cancer|Colo-rectal Cancer
|
June 2004 | Phase 1|Phase 2 |
NCT01280643 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Metastatic Colorectal Cancer
|
March 2010 | Not Applicable |
NCT03387111 | ImmunityBio, Inc. |
Squamous Cell Carcinoma
|
January 13, 2018 | Phase 1|Phase 2 |
NCT04751955 | Korean Cancer Study Group |
Colorectal Cancer Metastatic
|
January 1, 2022 | Phase 1|Phase 2 |
NCT04518280 | Fudan University |
Locally Advanced Rectal Cancer
|
May 1, 2021 | Phase 2 |
NCT03152370 | Adlai Nortye Biopharma Co., Ltd. |
Neoadjuvant Therapy in Rectal Cancer
|
May 17, 2017 | Phase 1 |
NCT00194779 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
October 2003 | Phase 2 |
NCT00749450 | Cancer Research UK, Glasgow |
Colorectal Cancer
|
March 2008 | Phase 3 |
NCT02316535 | West China Hospital |
Colorectal Neoplasms
|
November 2014 | Phase 3 |
NCT04394598 | Fudan University |
Locally Advanced Rectal Cancer
|
March 1, 2020 | Phase 2 |
NCT03745170 | Innovent Biologics (Suzhou) Co. Ltd. |
Gastric Cancer
|
December 19, 2018 | Phase 3 |
NCT04166318 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Canal Squamous Cell Carcinoma|Anal Margin Squamous Cell Carcinoma|Stage I Anal Cancer AJCC v8|Stage IIA Anal Cancer AJCC v8
|
November 12, 2019 | Phase 2 |
NCT04355858 | Fudan University |
Breast Cancer|Metastatic Cancer
|
May 1, 2020 | Phase 2 |
NCT01609127 | Genta Incorporated |
Locally Advanced Non-resectable Breast Cancer|Metastatic Breast Cancer
|
May 2012 | Phase 2 |
NCT04933227 | Hoffmann-La Roche |
Stomach Neoplasms|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
August 6, 2021 | Phase 2 |
NCT00148720 | Dana-Farber Cancer Institute|Hoffmann-La Roche|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Invasive Breast Carcinoma|Primary Invasive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
|
September 2004 | Phase 2 |
NCT01952951 | National Cancer Center, Korea|Korean Cancer Study Group |
Rectal Neoplasms|Adenocarcinoma
|
June 2014 | Phase 2 |
NCT03702985 | Fudan University |
Locally Advanced Rectal Cancer
|
May 28, 2018 | Phase 2 |
NCT04733963 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Colorectal Cancer
|
March 1, 2021 | Phase 2 |
NCT00741260 | Puma Biotechnology, Inc. |
Breast Cancer
|
December 9, 2008 | Phase 1|Phase 2 |
NCT00256321 | University of California, Irvine|Sanofi-Synthelabo |
Gastric Carcinoma|Gastroesophageal Junction Carcinoma
|
October 2004 | Phase 2 |
NCT02978612 | Oslo University Hospital |
Colon Cancer
|
June 2016 | Phase 2 |
NCT00680901 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Gastrointestinal Tract
|
June 4, 2008 | Phase 3 |
NCT00881816 | Nanjing Sike Pharmaceutical Co., Ltd. |
Advanced Gastric Carcinoma
|
April 2009 | Phase 1 |
NCT04456699 | Merck Sharp & Dohme LLC |
Metastatic Colorectal Cancer
|
August 19, 2020 | Phase 3 |
NCT03371017 | Hoffmann-La Roche |
Triple Negative Breast Neoplasms
|
January 11, 2018 | Phase 3 |
NCT01077739 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2009 | Phase 2 |
NCT05553522 | Baptist Health South Florida|Seagen Inc. |
Brain Metastases|HER2-positive Breast Cancer
|
October 2022 | Phase 1 |
NCT00335959 | Southwest Oncology Group|National Cancer Institute (NCI) |
Gastric Cancer
|
May 2006 | Phase 2 |
NCT04246502 | Shandong Cancer Hospital and Institute |
Metastatic Breast Cancer
|
January 2020 | Phase 2 |
NCT02872116 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Gastric Cancer|Gastroesophageal Junction Cancer|Esophageal Adenocarcinoma
|
October 12, 2016 | Phase 3 |
NCT03586869 | ImmunityBio, Inc. |
Pancreatic Cancer
|
July 28, 2018 | Phase 1|Phase 2 |
NCT00609336 | University of Washington|National Cancer Institute (NCI) |
Adenocarcinoma of the Pancreas|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer
|
January 2008 | Phase 2 |
NCT02574455 | Gilead Sciences |
Breast Cancer
|
November 7, 2017 | Phase 3 |
NCT00496587 | M.D. Anderson Cancer Center|Eli Lilly and Company |
Renal Cell Carcinoma|Kidney Cancer
|
July 2007 | Phase 2 |
NCT04789096 | Breast Cancer Trials, Australia and New Zealand |
Breast Cancer|HER2-positive Breast Cancer
|
December 2022 | Phase 2 |
NCT00613080 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Colorectal Cancer
|
April 2008 | Phase 2 |
NCT03950271 | Henan Cancer Hospital |
Gastric Cancer
|
January 21, 2020 | Phase 2 |
NCT01722162 | Washington University School of Medicine |
Colorectal Neoplasms
|
April 2013 | Phase 2 |
NCT02716766 | The University of Hong Kong |
Carcinoma, Hepatocellular|Secondary
|
March 2016 | Phase 2 |
NCT05254847 | Fudan University |
Biliary Tract Cancer
|
December 30, 2021 | Phase 2 |
NCT05609370 | BeiGene |
Unresectable or Metastatic Microsatellite Stable+Mismatch Repair Proficient Colorectal Cancer
|
November 2022 | Phase 1|Phase 2 |
NCT01135498 | Hoffmann-La Roche |
Colorectal Cancer
|
November 2006 | Phase 2 |
NCT01097018 | AEterna Zentaris |
Colorectal Cancer
|
April 2010 | Phase 3 |
NCT04720131 | Beijing Friendship Hospital |
Biliary Tract Cancer|Programmed Cell Death 1 Ligand 1 Gene Mutation|Targeted Molecular Therapy|Capecitabine
|
February 1, 2021 | Phase 2 |
NCT01729923 | University of Washington|National Cancer Institute (NCI) |
Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
|
March 2013 | Phase 2 |
NCT02921256 | National Cancer Institute (NCI)|NRG Oncology |
Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7
|
October 12, 2016 | Phase 2 |
NCT00816868 | Sun Yat-sen University |
Non-small Cell Lung Cancer
|
January 2009 | Phase 2 |
NCT00130533 | Spanish Breast Cancer Research Group|Hoffmann-La Roche|IBEROAMERICAN COALITION FOR BREAST ONCOLOGY RESEARCH (CIBOMA) |
Breast Cancer
|
January 2006 | Phase 3 |
NCT05007106 | Merck Sharp & Dohme LLC |
Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms
|
September 16, 2021 | Phase 2 |
NCT00425360 | Royal Liverpool University Hospital|National Cancer Institute (NCI) |
Pancreatic Cancer
|
September 2006 | Phase 3 |
NCT02754011 | UNICANCER|Novartis |
Breast Cancer
|
February 2, 2017 | Phase 1 |
NCT01150630 | IRCCS San Raffaele |
Pancreatic Cancer
|
May 2010 | Phase 2 |
NCT00314353 | NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute |
Colorectal Neoplasms
|
March 2006 | Phase 2 |
NCT00559676 | Centre Hospital Regional Universitaire de Limoges|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2005 | Phase 4 |
NCT05411380 | wang shusen|Sun Yat-sen University |
Breast Cancer
|
October 3, 2022 | Phase 2 |
NCT04768426 | Stanford University |
Triple Negative Breast Cancer|Breast Cancer
|
February 3, 2021 | Phase 2 |
NCT03615326 | Merck Sharp & Dohme LLC |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma
|
October 5, 2018 | Phase 3 |
NCT00316420 | Swedish Medical Center|Roche Pharma AG |
Pancreatic Cancer
|
December 2003 | Phase 1 |
NCT04068103 | NRG Oncology|National Cancer Institute (NCI) |
Colon Adenocarcinoma|Stage IIA Colon Cancer AJCC v8
|
December 16, 2019 | Phase 2|Phase 3 |
NCT01748773 | Hoffmann-La Roche |
Gastric Cancer|Gastroesophageal Junction Cancer
|
January 29, 2013 | Phase 2 |
NCT04132713 | First Affiliated Hospital of Harbin Medical University|Sponsor GmbH |
Microbiota
|
September 10, 2019 | |
NCT00659022 | Radboud University Medical Center |
Colorectal Neoplasms|Liver Neoplasms
|
July 2008 | Phase 2 |
NCT02314117 | Eli Lilly and Company |
Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
January 20, 2015 | Phase 3 |
NCT03828227 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Elderly Patients|Metastatic Colorectal Cancer|Quality of Life
|
June 7, 2019 | Phase 3 |
NCT00697502 | National University Hospital, Singapore |
Solid Tumors
|
May 2007 | Phase 1 |
NCT01655992 | Fudan University |
Metastatic Breast Cancer
|
January 2012 | Phase 3 |
NCT00602082 | Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI) |
Gastrointestinal Carcinoid Tumor|Islet Cell Tumor
|
August 2005 | Phase 2 |
NCT00967655 | Loma Linda Oncology Medical Group, Inc.|National Cancer Institute (NCI) |
Colorectal Cancer
|
July 2009 | Phase 2 |
NCT01843725 | Jules Bordet Institute |
Metastatic Colorectal Cancers|Metastatic Gastric Cancers|Metastatic Oesophageal Cancers|Metastatic Pancreatic Cancers|Metastatic Biliary Cancers|Metastatic Breast Cancers
|
September 2013 | Phase 1 |
NCT00104689 | UNICANCER |
Colorectal Cancer
|
June 30, 2003 | Phase 2 |
NCT02445391 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Estrogen Receptor Negative|HER2+Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
April 29, 2015 | Phase 3 |
NCT00541112 | UNICANCER |
Colorectal Cancer
|
October 29, 2007 | Phase 2 |
NCT04753203 | Korean Cancer Study Group |
Metastatic Colorectal Cancer|PIK3CA Gene Mutation
|
February 28, 2021 | Phase 1|Phase 2 |
NCT03959150 | Ruijin Hospital |
Pancreatic Cancer
|
January 5, 2020 | Phase 2|Phase 3 |
NCT00891878 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer
|
August 2009 | Phase 2 |
NCT00744640 | University Hospital, Basel, Switzerland|Swiss National Science Foundation|Swiss Cancer League|Roche Pharma AG|Sanofi |
Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer
|
October 2005 | Phase 1|Phase 2 |
NCT00811135 | Hoffmann-La Roche |
Breast Cancer
|
December 2008 | Phase 2 |
NCT00254137 | Ludwig-Maximilians - University of Munich|Merck Sharp & Dohme LLC|Sanofi|Pfizer|Hoffmann-La Roche |
Metastatic Colorectal Cancer
|
September 2004 | Phase 2 |
NCT00005839 | City of Hope Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2000 | Phase 1 |
NCT05489211 | AstraZeneca|Daiichi Sankyo, Inc. |
Endometrial Cancer|Gastric Cancer|Metastatic Castration-resistant Prostate Cancer|Ovarian Cancer|Colorectal Cancer
|
September 6, 2022 | Phase 2 |
NCT01584544 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Rectal Neoplasms
|
January 2011 | Phase 1 |
NCT00084734 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
May 2002 | Phase 1 |
NCT05290194 | Fifth Affiliated Hospital, Sun Yat-Sen University |
Radiotherapy|PD-1 Inhibitor|Capecitabine|Nasopharyngeal Carcinoma
|
March 28, 2022 | Phase 2 |
NCT00266799 | Merck Sharp & Dohme LLC|Essex Pharma GmbH |
Breast Cancer
|
January 13, 2006 | Phase 3 |
NCT00114179 | National Cancer Institute (NCI)|NRG Oncology |
Adenocarcinoma of the Pancreas|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer
|
January 2005 | Phase 2 |
NCT00568529 | Fudan University |
Gastric Cancer
|
October 2007 | Phase 2 |
NCT01824875 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Gastrinoma|Glucagonoma|Insulinoma|Islet Cell Carcinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma
|
April 11, 2013 | Phase 2 |
NCT00124527 | Eisai Inc. |
Thyroid Cancer
|
March 31, 2005 | Phase 2 |
NCT00114816 | Finnish Breast Cancer Group|Hoffmann-La Roche|Sanofi|AstraZeneca |
Breast Cancer
|
January 2004 | Phase 3 |
NCT03451370 | Istituto Oncologico Veneto IRCCS |
Elderly Metastatic Colorectal Cancer Patients
|
November 1, 2017 | |
NCT00613145 | SCRI Development Innovations, LLC|Bayer |
Refractory Malignancy
|
February 2008 | Phase 1 |
NCT01308086 | Hellenic Oncology Research Group|University Hospital of Crete |
CRC
|
October 2010 | Phase 3 |
NCT00227747 | UNICANCER |
Colorectal Cancer
|
November 8, 2005 | Phase 3 |
NCT01493336 | Hoffmann-La Roche |
Breast Cancer, Colorectal Cancer
|
May 2012 | Phase 1 |
NCT02717923 | Huazhong University of Science and Technology|The First Affiliated Hospital of Nanchang University|Hunan Cancer Hospital|Henan Cancer Hospital |
Colorectal Neoplasms
|
January 2014 | Phase 2 |
NCT00929240 | Hoffmann-La Roche |
Breast Cancer
|
July 2009 | Phase 3 |
NCT00030732 | Swiss Group for Clinical Cancer Research|Central European Cooperative Oncology Group |
Pancreatic Cancer
|
June 2001 | Phase 3 |
NCT05212454 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer|Chemotherapy Effect
|
January 2023 | Phase 3 |
NCT00555620 | Pfizer |
Stomach Neoplasms
|
May 2008 | Phase 1 |
NCT03817411 | Taizhou EOC Pharma Co., Ltd.|Shanghai East Hospital|Shanghai Zhongshan Hospital |
Gastric Cancer
|
January 25, 2019 | Phase 2 |
NCT04390958 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Squamous Cell Carcinoma
|
May 15, 2020 | Phase 2 |
NCT01589419 | AbbVie (prior sponsor, Abbott)|AbbVie |
Locally Advanced Rectal Cancer
|
June 2012 | Phase 1 |
NCT00504660 | M.D. Anderson Cancer Center |
Anaplastic Glioma of Brain|Glioblastoma Multiforme|Brain Cancer
|
September 2003 | Phase 2 |
NCT03854799 | Gruppo Oncologico del Nord-Ovest |
Colon Rectal Cancer
|
April 1, 2019 | Phase 2 |
NCT00303927 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Pancreatic Cancer
|
December 2005 | Phase 2 |
NCT00433550 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Pfizer|Sanofi |
Small Intestine Adenocarcinoma|Recurrent Small Intestine Cancer
|
May 2007 | Phase 2 |
NCT02767752 | Herlev Hospital|GENIS |
Pancreatic Cancer
|
November 2016 | Phase 2 |
NCT02361112 | Jiangsu HengRui Medicine Co., Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Metastatic Breast Cancer
|
August 2014 | Phase 1 |
NCT02625610 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
|
December 24, 2015 | Phase 3 |
NCT01332604 | Genentech, Inc. |
Solid Cancers
|
July 2011 | Phase 1 |
NCT04809142 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Advanced Biliary Cancer
|
February 4, 2021 | Phase 3 |
NCT00227734 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
June 2004 | Phase 2 |
NCT00417209 | Sanofi |
Pancreatic Neoplasms
|
December 2006 | Phase 3 |
NCT05417386 | Colin D. Weekes, M.D.|Novartis|Massachusetts General Hospital |
Pancreas Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma
|
August 9, 2022 | Phase 1 |
NCT00263029 | Sanofi |
Rectal Neoplasms
|
June 2002 | Phase 2 |
NCT00473005 | Stanford University|Novartis |
Breast Cancer
|
August 2007 | Phase 1 |
NCT04965064 | University of Rochester |
Breast Cancer
|
September 23, 2022 | Phase 2 |
NCT05265208 | Center Eugene Marquis |
Resectable Intrahepatic Cholangiocarcinoma
|
February 4, 2022 | Phase 2 |
NCT00277069 | University of New Mexico |
Breast|Cancer
|
May 2000 | Phase 1|Phase 2 |
NCT00216021 | Hoosier Cancer Research Network|Sanofi|Hoffmann-La Roche|Walther Cancer Institute |
Metastatic Breast Cancer
|
March 2004 | Phase 2 |
NCT00251186 | University of Medicine and Dentistry of New Jersey|Rutgers Cancer Institute of New Jersey|Bristol-Myers Squibb|Rutgers, The State University of New Jersey |
Colorectal Cancer
|
April 2006 | Phase 2 |
NCT03678649 | Zhejiang Cancer Hospital |
Head and Neck Neoplasms
|
September 10, 2018 | Phase 2 |
NCT00675194 | Johannes Gutenberg University Mainz |
Gastric Cancer
|
October 2003 | Phase 2 |
NCT00958737 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Colorectal Cancer
|
May 12, 2009 | Phase 3 |
NCT04089150 | Australasian Gastro-Intestinal Trials Group|Trans Tasman Radiation Oncology Group|Australian Government Department of Health and Ageing |
Pancreatic Cancer
|
October 1, 2019 | Phase 2 |
NCT00006812 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 2001 | Phase 2 |
NCT00795678 | Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2008 | |
NCT00967031 | UNICANCER |
Breast Cancer|Metastatic Cancer
|
April 2009 | Phase 2 |
NCT03523585 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
August 1, 2018 | Phase 3 |
NCT00031876 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
May 2000 | Phase 1|Phase 2 |
NCT00004187 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
June 1999 | Phase 1|Phase 2 |
NCT01234324 | AIO-Studien-gGmbH|Amgen|WiSP Wissenschaftlicher Service Pharma GmbH |
Stomach Neoplasms|Gastroesophageal Junction Neoplasms
|
October 2010 | Phase 2 |
NCT02581423 | Hoffmann-La Roche |
Colorectal Cancer
|
August 2005 | Phase 4 |
NCT00551096 | University of Colorado, Denver|AstraZeneca |
Malignant Solid Tumour|Biliary Cancer|Pancreatic Cancer
|
October 2007 | Phase 1 |
NCT04621370 | Liz-Anne Lewsley|University of Glasgow|AstraZeneca|NHS Greater Glasgow and Clyde|Cancer Research UK, Glasgow |
Rectal Cancer|Rectal Adenocarcinoma|Rectal Neoplasms
|
December 7, 2020 | Phase 2 |
NCT01846650 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Metastatic Breast Cancer or Metastatic Colorectal Cancer
|
December 2012 | Phase 1 |
NCT03579758 | Emory University |
Stage I Gallbladder Cancer AJCC v8|Stage II Gallbladder Cancer AJCC v8|Stage IIA Gallbladder Cancer AJCC v8|Stage IIB Gallbladder Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8
|
April 3, 2019 | Phase 3 |
NCT04911517 | Beijing Friendship Hospital|Hangzhou New Horizon Health Technology Co., Ltd.|Beigene (Beijing) Biotechnology Co., Ltd|Beijing Chao Yang Hospital|Xuanwu Hospital, Beijing|Tianjin Medical University General Hospital|People´s Hospital of Tianjin|Tianjin Medical University Cancer Institute & Hospital |
Colorectal Neoplasms
|
June 1, 2021 | Phase 2 |
NCT04646759 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
October 14, 2020 | Phase 3 |
NCT00226980 | Stanford University|Celgene Corporation |
Kidney Neoplasms
|
October 2002 | Phase 2 |
NCT00777101 | Puma Biotechnology, Inc. |
Advanced Breast Cancer|Breast Cancer
|
February 4, 2009 | Phase 2 |
NCT01725386 | Hoffmann-La Roche |
Breast Cancer
|
March 2011 | |
NCT00064181 | European Organisation for Research and Treatment of Cancer - EORTC |
Colorectal Cancer
|
May 2003 | Phase 3 |
NCT03852251 | Akeso|Akeso Pharmaceuticals, Inc. |
Gastric Adenocarcinoma|Advanced Solid Tumors|Gastroesophageal Junction Adenocarcinoma
|
January 18, 2019 | Phase 1|Phase 2 |
NCT00821912 | Karolinska University Hospital |
Cancer of the Esophagus|Gastric Cardia Carcinoma
|
March 2006 | Phase 1|Phase 2 |
NCT00580359 | National Cancer Center, Korea |
Stomach Neoplasms
|
May 2007 | Phase 2 |
NCT02524275 | University of Nebraska |
Head and Neck Squamous Cell Carcinoma
|
March 30, 2015 | Phase 2 |
NCT00950820 | AIO-Studien-gGmbH|iOMEDICO AG |
Colorectal Neoplasms
|
September 2009 | Phase 2 |
NCT00121251 | National Cancer Institute (NCI) |
Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7
|
June 3, 2005 | Phase 1|Phase 2 |
NCT00858429 | Northwestern University |
Liver Cancer|Metastatic Cancer
|
April 1, 2009 | Phase 1 |
NCT03869892 | Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier |
Metastatic Colorectal Cancer
|
March 21, 2019 | Phase 3 |
NCT00278863 | Asan Medical Center |
Gastric Cancer
|
November 2004 | Phase 2 |
NCT02576964 | Hoffmann-La Roche |
Carcinoma, Hepatocellular
|
January 2005 | Phase 2 |
NCT04571437 | Cairo University |
Breast Cancer|Estrogen Receptor-positive Breast Cancer|Metastatic Breast Cancer
|
March 1, 2020 | Phase 2 |
NCT01013740 | Novartis Pharmaceuticals|Novartis |
Cancer
|
November 25, 2009 | Phase 2 |
NCT00532714 | National Cancer Center, Korea |
Breast Cancer Metastatic
|
August 2006 | Phase 2 |
NCT00548548 | Genentech, Inc.|Hoffmann-La Roche|Chugai Pharmaceutical |
Adenocarcinoma
|
September 2007 | Phase 3 |
NCT02623153 | Tianshu Liu|Shanghai Zhongshan Hospital |
Gastric Cancer
|
January 2016 | Phase 2 |
NCT04703101 | Jonsson Comprehensive Cancer Center |
Locally Advanced Rectal Carcinoma|Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v8|Stage IIA Rectal Cancer AJCC v8|Stage IIB Rectal Cancer AJCC v8|Stage IIC Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8
|
February 11, 2021 | Phase 1 |
NCT05344742 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Advanced Solid Tumor
|
April 2022 | Phase 1 |
NCT00350961 | Rigshospitalet, Denmark|Henrik Jensen, Dept. of Oncology, Vejle Sygehus, Vejle, Denmark |
Cholangiocarcinoma
|
June 2004 | Phase 1|Phase 2 |
NCT01501669 | National Cancer Center, Korea|Asan Medical Center|Chung-Ang University|Inha University Hospital|Korea University Anam Hospital|Samsung Medical Center|Severance Hospital|Seoul National University Hospital|Seoul National University Bundang Hospital |
Metastatic Breast Cancer
|
June 2011 | Phase 3 |
NCT03169764 | ImmunityBio, Inc. |
Head and Neck Squamous Cell Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT01558869 | The University of Hong Kong |
Pancreatic Adenocarcinoma
|
April 2012 | Phase 2 |
NCT03756298 | National Cancer Center, Korea |
Triple Negative Breast Cancer
|
January 15, 2019 | Phase 2 |
NCT00073905 | Swiss Group for Clinical Cancer Research |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer|Pain
|
April 2003 | Phase 2 |
NCT04488159 | Johannes Laengle, MD, PhD|Medical University of Vienna |
Colon Cancer Stage III
|
December 1, 2022 | Phase 3 |
NCT02605265 | Fudan University|The First Affiliated Hospital with Nanjing Medical University|Hubei Cancer Hospital|First Affiliated Hospital of Chongqing Medical University|Ruijin Hospital |
Locally Advanced Rectal Cancer
|
October 2015 | Phase 3 |
NCT04247984 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Hospital|Henan Cancer Hospital|Liaoning Tumor Hospital & Institute|Jiangsu Cancer Institute & Hospital |
Metastatic Colorectal Cancer
|
May 1, 2018 | Phase 2 |
NCT00882310 | Columbia University |
Pancreatic Cancer
|
September 2006 | Phase 2 |
NCT01661972 | John Strickler, M.D.|Sanofi|Duke University |
Metastatic Colorectal Cancer
|
August 2012 | Phase 1|Phase 2 |
NCT00215501 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Solid Tumor
|
November 2001 | Phase 1 |
NCT02860234 | Peking University Cancer Hospital & Institute |
Rectal Cancer
|
August 2016 | |
NCT04339036 | Abramson Cancer Center of the University of Pennsylvania|Roswell Park Cancer Institute|CARTI |
Neuroendocrine Tumor Grade 2|Neuroendocrine Tumors
|
October 7, 2021 | Phase 2 |
NCT00069095 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2003 | Phase 3 |
NCT01702558 | Hoffmann-La Roche |
Breast Cancer|Gastric Cancer
|
December 3, 2012 | Phase 2 |
NCT01227707 | Hoffmann-La Roche |
Colorectal Cancer
|
November 2005 | Phase 2 |
NCT03368131 | Hebei Medical University |
Gastroesophageal Junction Adenocarcinoma
|
December 1, 2017 | Phase 2 |
NCT01070290 | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) |
Gastric Cancer
|
Phase 2 | |
NCT00010023 | NYU Langone Health|National Cancer Institute (NCI) |
Cancer
|
August 2000 | Phase 1 |
NCT00397761 | Medstar Health Research Institute |
Breast Cancer
|
July 2006 | Phase 2|Phase 3 |
NCT03169738 | ImmunityBio, Inc. |
Non-small Cell Lung Cancer
|
February 2018 | Phase 1|Phase 2 |
NCT04158362 | UNICANCER |
Cancer Metastatic
|
June 11, 2020 | Phase 3 |
NCT00600340 | Central European Cooperative Oncology Group |
Metastatic Breast Cancer
|
April 2008 | Phase 3 |
NCT04662710 | Merck Sharp & Dohme LLC|Eisai Inc. |
Advanced+Metastatic Gastroesophageal Adenocarcinoma
|
December 30, 2020 | Phase 3 |
NCT02354612 | Tracon Pharmaceuticals Inc. |
Solid Tumors
|
||
NCT04008511 | China Medical University, China|Liaoning Tumor Hospital & Institute|The First People´s Hospital of Jingzhou |
Metastatic Colorectal Cancer
|
July 2019 | Phase 1|Phase 2 |
NCT04411524 | Fudan University |
Locally Advanced Rectal Cancer
|
July 1, 2020 | Phase 2 |
NCT01917279 | Binghe Xu|Hoffmann-La Roche|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Neoplasms|Neoplasms by Site|Neoplasm Metastasis|Breast Diseases|Skin Diseases
|
October 2013 | Phase 3 |
NCT05091528 | Silverback Therapeutics |
HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer
|
February 8, 2022 | Phase 1|Phase 2 |
NCT01077726 | Hoffmann-La Roche |
Breast Cancer
|
January 2010 | Phase 2 |
NCT04942626 | Goethe University |
Rectal Cancer
|
August 20, 2021 | Phase 1 |
NCT01022541 | Royal Marsden NHS Foundation Trust|Roche Pharma AG |
Metastatic Colorectal Cancer
|
June 2006 | Phase 2 |
NCT03129074 | Aslan Pharmaceuticals |
Advanced or Metastatic Biliary Tract Cancer
|
May 2018 | Phase 2 |
NCT00352378 | National Cancer Center, Korea |
Breast Cancer
|
June 2002 | Phase 3 |
NCT02611960 | Merck Sharp & Dohme LLC |
Nasopharyngeal Neoplasms
|
April 18, 2016 | Phase 3 |
NCT02114359 | Seoul National University Hospital|Ministry of Health & Welfare, Korea|Korean Cancer Study Group |
Gastric Cancer
|
February 2014 | Phase 3 |
NCT02009449 | Eli Lilly and Company|ARMO BioSciences |
Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer
|
November 15, 2013 | Phase 1 |
NCT04522284 | National University Hospital, Singapore|The N.1 Institute for Health (N.1) |
Solid Tumor
|
August 20, 2020 | Phase 1|Phase 2 |
NCT03175666 | ImmunityBio, Inc. |
Triple Negative Breast Cancer
|
December 2017 | Phase 1|Phase 2 |
NCT01013649 | National Cancer Institute (NCI)|NRG Oncology |
Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7
|
November 17, 2009 | Phase 3 |
NCT01935492 | Borstkanker Onderzoek Groep|Roche Pharma AG|Teva Pharma |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Metastatic Breast Cancer
|
November 2010 | Phase 3 |
NCT04304209 | Sun Yat-sen University |
Colorectal Cancer Stage II|Colorectal Cancer Stage III|Mmr Deficiency|MSI-H
|
October 18, 2019 | Phase 2|Phase 3 |
NCT05535413 | Hunan Cancer Hospital |
Metastatic HER2 Negative Breast Carcinoma|Brain Metastases|Capecitabine|UDT1
|
August 1, 2022 | Phase 1|Phase 2 |
NCT00291486 | Ludwig Institute for Cancer Research|National Cancer Institute (NCI) |
Colorectal Neoplasms
|
October 2003 | Phase 1 |
NCT01573468 | Genta Incorporated |
Gastric Carcinoma
|
April 2012 | Phase 2 |
NCT04615013 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Cervical Esophagus Adenocarcinoma|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Gastroesophageal Junction Adenocarcinoma|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Thoracic Esophagus Adenocarcinoma
|
November 23, 2020 | Phase 1 |
NCT00645866 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Cancer
|
April 2003 | Phase 2 |
NCT03764553 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Servier |
Esophageal Cancer
|
May 1, 2019 | Phase 2 |
NCT00204776 | University of Wisconsin, Madison|Sanofi |
Metastatic Breast Cancer
|
March 2005 | Phase 2 |
NCT00142480 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Genentech, Inc.|Sanofi-Synthelabo|Hoffmann-La Roche |
Biliary Tract Cancer|Gallbladder Adenocarcinoma
|
December 2004 | Phase 2 |
NCT05438706 | Fudan University |
Triple-negative Breast Cancer
|
July 10, 2022 | Phase 2 |
NCT00093808 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
August 2004 | Phase 2 |
NCT04550260 | AstraZeneca |
Esophageal Squamous Cell Carcinoma
|
October 19, 2020 | Phase 3 |
NCT00604409 | Fox Chase Cancer Center|Sirtex Medical |
Metastatic Liver Cancer
|
April 2006 | Phase 1 |
NCT00196859 | German Breast Group|Hoffmann-La Roche|AstraZeneca |
Breast Cancer
|
June 2004 | Phase 3 |
NCT00540800 | National Cancer Institute, Naples |
Breast Cancer
|
February 2004 | Phase 3 |
NCT00039442 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Recurrent Cervical Carcinoma
|
April 29, 2002 | Phase 2 |
NCT00201734 | Ohio State University Comprehensive Cancer Center|Roche Pharma AG |
Tumors|Unknown Primary Tumors|Adenocarcinoma
|
June 2005 | Phase 1|Phase 2 |
NCT05608785 | Henan Cancer Hospital |
Gastric Cancer|Gastroesophageal-junction Cancer
|
January 1, 2023 | Phase 1|Phase 2 |
NCT01918527 | Vejle Hospital |
Colon Cancer
|
September 2013 | Phase 3 |
NCT00421824 | Sanofi |
Rectal Neoplasms
|
May 2006 | Phase 2 |
NCT00129935 | Spanish Breast Cancer Research Group|Sanofi|Hoffmann-La Roche|Pfizer |
Breast Cancer
|
February 2004 | Phase 3 |
NCT01229813 | Lund University Hospital|Hoffmann-La Roche |
Colorectal Cancer
|
October 2010 | Phase 3 |
NCT04119622 | Aiping Zhou|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Gastric Cancer Stage II|Gastric Cancer Stage III
|
October 8, 2019 | Phase 2 |
NCT03781362 | Coordination Pharmaceuticals, Inc. |
Advanced Tumors
|
December 21, 2018 | Phase 1 |
NCT04854668 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Metastatic Colorectal Cancer
|
May 27, 2021 | Phase 3 |
NCT02451553 | University of Washington |
Advanced Malignant Solid Neoplasm|Bile Duct Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer
|
November 5, 2015 | Phase 1 |
NCT02550743 | howard safran|Brown University|Lifespan|Novartis Pharmaceuticals Corporation (Financial supporter) |
Rectal Cancer
|
June 3, 2016 | Phase 1 |
NCT00887822 | Hoffmann-La Roche |
Gastric Cancer
|
March 2009 | Phase 3 |
NCT01935778 | Asan Medical Center|Seoul National University Bundang Hospital|Severance Hospital|Inha University Hospital|Hallym University Medical Center |
Gastric Cancer, Adjuvant Chemotherapy, XO
|
September 2013 | Phase 3 |
NCT04262804 | Zai Lab (Shanghai) Co., Ltd.|Zai Lab (Hong Kong), Ltd. |
Breast Cancer Metastatic
|
January 13, 2020 | Phase 2 |
NCT00093379 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Anal Cancer
|
April 2004 | Phase 2 |
NCT01765582 | Hoffmann-La Roche |
Colorectal Neoplasms
|
January 23, 2013 | Phase 2 |
NCT00726687 | Alaunos Therapeutics |
Advanced Solid Tumors
|
June 2008 | Phase 1|Phase 2 |
NCT05479240 | Fujian Cancer Hospital |
Immunotherapy
|
September 1, 2022 | Phase 2 |
NCT00127933 | Hoffmann-La Roche |
Breast Cancer
|
August 2005 | Phase 4 |
NCT01705106 | University of Chicago|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 29, 2012 | Phase 1 |
NCT00153881 | Dartmouth-Hitchcock Medical Center|Sanofi|Hoffmann-La Roche |
Esophageal Neoplasms
|
February 2000 | Phase 1 |
NCT01996306 | Epidemiological and Clinical Research Information Network |
Colorectal Neoplasms|Neoplasm Metastasis|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms
|
December 2, 2013 | Phase 3 |
NCT04443543 | Fudan University |
Rectal Cancer
|
June 22, 2020 | Phase 2 |
NCT00288002 | German Breast Group|National Cancer Institute (NCI) |
Breast Cancer
|
January 2005 | Phase 3 |
NCT00508274 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
July 18, 2007 | Phase 3 |
NCT00439426 | Hoffmann-La Roche |
Nasopharyngeal Cancer
|
April 2007 | Phase 2 |
NCT00854477 | Cambridge University Hospitals NHS Foundation Trust |
Pancreatic Adenocarcinoma
|
November 2009 | Phase 4 |
NCT01231802 | Adherex Technologies, Inc. |
Metastatic Breast Cancer
|
April 2011 | Phase 2 |
NCT00070434 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
August 2004 | Phase 2 |
NCT00479856 | GlaxoSmithKline |
Relapsed Breast Cancer|Neoplasms, Breast
|
November 2007 | Phase 2 |
NCT03805399 | Fudan University |
Triple-negative Breast Cancer
|
October 18, 2018 | Phase 1|Phase 2 |
NCT03448835 | The Netherlands Cancer Institute|Hoffmann-La Roche |
Stomach Cancer|Gastro Esophageal Junction Cancer
|
March 7, 2018 | Phase 2 |
NCT02120417 | Incyte Corporation |
Breast Cancer
|
May 2014 | Phase 2 |
NCT02831179 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IV Merkel Cell Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome
|
December 2017 | Phase 1 |
NCT02741856 | Lisette Nixon|Cancer Research UK|Velindre NHS Trust |
Oesophageal Cancer
|
November 4, 2016 | Phase 2|Phase 3 |
NCT01823679 | Stanford University|National Cancer Institute (NCI) |
Squamous Cell Carcinoma of the Skin|Recurrent Skin Cancer
|
March 2013 | Phase 2 |
NCT02143388 | Zhao Chong|Jiangxi Provincial Cancer Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|National Cancer Centre, Singapore|Sun Yat-sen University |
Local Advanced High Risk Nasopharyngeal Carcinoma
|
March 31, 2014 | Phase 3 |
NCT03026803 | City of Hope Medical Center|Sanofi |
Liver Cancer|Hepatocellular Cancer
|
November 2006 | Phase 2 |
NCT04595565 | German Breast Group|Gilead Sciences|Austrian Breast & Colorectal Cancer Study Group|Spanish Breast Cancer Research Group (GEICAM)|ETOP IBCSG Partners Foundation|Cancer Trials Ireland|UNICANCER |
HER2-negative Breast Cancer|Triple Negative Breast Cancer
|
October 28, 2020 | Phase 3 |
NCT00509561 | Wales Cancer Trials Unit|Cancer Research UK |
Esophageal Cancer
|
February 2008 | Phase 2|Phase 3 |
NCT00427713 | Cancer Research UK|National Cancer Institute (NCI) |
Colorectal Cancer
|
November 2004 | Phase 3 |
NCT00107393 | Tohoku University|National Cancer Institute (NCI) |
Breast Cancer
|
June 2003 | Phase 2 |
NCT02371304 | Amsterdam UMC, location VUmc |
Rectal Cancer
|
October 2015 | Phase 3 |
NCT00916578 | M.D. Anderson Cancer Center |
Breast Cancer
|
June 5, 2009 | Phase 2 |
NCT02042443 | National Cancer Institute (NCI) |
Adult Cholangiocarcinoma|Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage D Adult Hepatocellular Carcinoma|Hilar Cholangiocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma|Recurrent Childhood Liver Cancer|Recurrent Extrahepatic Bile Duct Carcinoma|Recurrent Gallbladder Carcinoma|Stage II Gallbladder Cancer|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IV Childhood Hepatocellular Carcinoma|Stage IV Distal Bile Duct Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Carcinoma
|
February 2014 | Phase 2 |
NCT02529774 | Ye Xu|Fudan University |
Resected Liver Metastases From Colorectal Cancer
|
September 2015 | Phase 2|Phase 3 |
NCT00842491 | Peking University|Xiansheng Pharmaceutical Company |
Advanced Gastric Cancer
|
November 2008 | Phase 2 |
NCT00437294 | Eli Lilly and Company |
Breast Cancer
|
March 2007 | Phase 2 |
NCT00865982 | Charite University, Berlin, Germany|Roche Pharma AG|Sanofi |
Gastric Cancer|Esophageal Cancer
|
September 2008 | Phase 2 |
NCT02117479 | Incyte Corporation |
Pancreatic Cancer
|
March 2014 | Phase 3 |
NCT01226732 | SCRI Development Innovations, LLC|Novartis Pharmaceuticals |
Metastatic or Unresectable Solid Tumor Malignancy
|
November 2010 | Phase 1 |
NCT00526669 | GlaxoSmithKline |
Neoplasms, Gastrointestinal Tract
|
March 2008 | Phase 2 |
NCT00444678 | NYU Langone Health|Eli Lilly and Company|Bristol-Myers Squibb |
Colorectal Cancer|Neoplasm Metastasis
|
June 1, 2004 | Phase 2 |
NCT00281788 | Duke University|National Cancer Institute (NCI) |
Esophageal Cancer
|
September 2003 | Phase 1 |
NCT00081536 | Aronex Pharmaceuticals |
Colorectal Neoplasms
|
Phase 1|Phase 2 | |
NCT00482222 | University of Southampton|University Hospital Southampton NHS Foundation Trust |
Colorectal Cancer|Metastatic Cancer
|
February 2007 | Phase 3 |
NCT02071043 | Shanghai Zhongshan Hospital |
Advanced Gastric Cancer
|
November 2008 | Phase 2 |
NCT05144854 | Ono Pharmaceutical Co. Ltd |
Gastric Cancer
|
November 5, 2021 | Phase 3 |
NCT00118755 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2005 | Phase 2 |
NCT02268006 | Institute of Oncology Ljubljana |
Rectal Carcinoma
|
January 2014 | Phase 2 |
NCT02350686 | Samsung Medical Center |
Biliary Tract Cancer
|
May 14, 2015 | Phase 2 |
NCT03197571 | ImmunityBio, Inc. |
Urothelial Carcinoma
|
December 2017 | Phase 1|Phase 2 |
NCT04001621 | Fudan University |
Metastatic Breast Cancer
|
June 26, 2019 | Phase 2 |
NCT00625183 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Colorectal Cancer
|
March 2008 | Phase 2 |
NCT04861987 | Processa Pharmaceuticals |
Advanced Cancer|Refractory Cancer|Tumor Gastric
|
June 18, 2021 | Phase 1 |
NCT00960349 | AstraZeneca |
Gastric Cancer
|
August 2009 | Phase 1 |
NCT00662025 | Pfizer |
Advanced+Metastatic Breast Cancer
|
April 2008 | Phase 2 |
NCT00216073 | Hoosier Cancer Research Network|Sanofi|Hoffmann-La Roche|Walther Cancer Institute |
Metastatic Breast Cancer
|
March 2004 | Phase 2 |
NCT00226798 | Rambam Health Care Campus|Roche Pharma AG |
Adenocarcinoma Clear Cell
|
December 2003 | Phase 2 |
NCT00532948 | Hoffmann-La Roche |
Glioma
|
May 2007 | Phase 1 |
NCT00601510 | Technical University of Munich |
Gastric Cancer
|
November 2007 | Phase 1 |
NCT04937738 | Ukrainian Society of Clinical Oncology |
Gastric Cancer
|
July 21, 2021 | Phase 2 |
NCT03950154 | Tianjin Medical University Cancer Institute and Hospital |
Colorectal Cancer
|
June 1, 2019 | Phase 3 |
NCT00885755 | Hoffmann-La Roche |
Breast Cancer
|
August 13, 2009 | Phase 2 |
NCT02555657 | Merck Sharp & Dohme LLC |
Metastatic Triple Negative Breast Cancer
|
October 13, 2015 | Phase 3 |
NCT02465593 | PharmaEngine |
Rectal Cancer
|
June 2015 | Phase 1|Phase 2 |
NCT00459901 | Peter Kozuch|Hoffmann-La Roche|Genentech, Inc.|Beth Israel Medical Center |
Metastatic Colorectal Cancer
|
June 2004 | Phase 2 |
NCT05412082 | University of Miami |
Locally Advanced Rectal Cancer
|
October 5, 2022 | Phase 1 |
NCT01433614 | Thomas Hatschek|Karolinska University Hospital |
Metastatic Breast Cancer
|
December 2002 | Phase 3 |
NCT00414271 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Stage T3-4NxM0 Gastric Cancer
|
January 2006 | Phase 2 |
NCT03523312 | Memorial Sloan Kettering Cancer Center |
Pancreatic Cancer
|
April 30, 2018 | Phase 2 |
NCT00796718 | Hoffmann-La Roche |
Colorectal Cancer
|
October 2008 | Phase 2 |
NCT00618124 | Pfizer |
Solid Tumors|Breast Cancer|Neoplasms
|
May 2005 | Phase 1 |
NCT05568095 | Arcus Biosciences, Inc.|Gilead Sciences |
Advanced Upper Gastrointestinal Tract Adenocarcinoma
|
November 2022 | Phase 3 |
NCT00398879 | AEterna Zentaris |
Colon Cancer
|
August 2005 | Phase 2 |
NCT01134601 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Non-Metastatic Adenocarcinoma of the Rectum
|
May 24, 2010 | Phase 1 |
NCT02560298 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer
|
February 1, 2016 | Phase 2 |
NCT00480597 | Ludwig-Maximilians - University of Munich |
Metastatic Breast Cancer
|
October 2002 | Phase 2 |
NCT00212589 | Odense University Hospital |
Colorectal Cancer
|
December 2002 | Phase 3 |
NCT05251948 | Hoffmann-La Roche |
Gastric and Gastroesophageal Junction Carcinoma
|
March 1, 2022 | Phase 1|Phase 2 |
NCT05625412 | Bristol-Myers Squibb |
Advanced Solid Tumors
|
November 29, 2022 | Phase 1 |
NCT01355302 | Eisai Inc.|Quintiles, Inc. |
Advanced or Metastatic Solid Tumors|Previously Untreated Gastric Cancer
|
November 2011 | Phase 1|Phase 2 |
NCT00220168 | Royal Marsden NHS Foundation Trust |
Upper Gastrointestinal Tumours
|
January 2003 | Phase 4 |
NCT00639522 | Nanjing Sike Pharmaceutical Co., Ltd. |
Gastric Carcinoma
|
May 2008 | Phase 1 |
NCT04281576 | NovoCure GmbH|Zai Lab (Shanghai) Co., Ltd.|NovoCure Ltd. |
Gastric Cancer|GastroEsophageal Cancer
|
December 19, 2019 | Not Applicable |
NCT01843829 | Lisette Nixon|Cancer Research UK|Velindre NHS Trust |
Oesophageal Cancer
|
October 2013 | Phase 2 |
NCT00119314 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Carcinoma of Unknown Primary
|
July 2004 | Phase 2 |
NCT00238147 | University of Washington |
Esophageal Cancer
|
September 2004 | Phase 1 |
NCT00004012 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
December 1998 | Phase 2 |
NCT00647530 | University of Birmingham |
Colorectal Cancer
|
May 15, 2008 | Phase 2|Phase 3 |
NCT03403049 | Albert Einstein College of Medicine|Shanghai Proton and Heavy Ion Center |
Pancreatic Cancer|Cancer
|
April 1, 2016 | Phase 1 |
NCT01821612 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer
|
May 2013 | Early Phase 1 |
NCT02027363 | Sun Yat-sen University |
Colorectal Neoplasms|Neoplasms Metastasis
|
January 2010 | Phase 2 |
NCT00101075 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Sanofi-Synthelabo |
Head and Neck Cancer
|
October 2004 | Phase 2 |
NCT01196260 | State Key Laboratory of Cancer Biology|Tianjin Union Medical Center|Beihua University|Chengdu Medical College|Shanghai Jiao Tong University School of Medicine |
Colorectal Cancer
|
January 2004 | Phase 2|Phase 3 |
NCT00084942 | Roswell Park Cancer Institute |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer
|
October 2002 | Phase 2 |
NCT00452673 | Bristol-Myers Squibb |
Advanced Breast Cancer
|
June 2007 | Phase 1 |
NCT04134897 | Blokhin´s Russian Cancer Research Center |
Rectal Neoplasms Malignant|Rectum Carcinoma|Rectal Cancer
|
October 14, 2019 | Phase 3 |
NCT00450203 | Professor David Cunningham|Cancer Research UK|Roche Pharma AG|GlaxoSmithKline|Medical Research Council |
Oesophagogastric Cancer
|
October 2007 | Phase 2|Phase 3 |
NCT00842244 | Pfizer |
Stomach Neoplasms|Advanced Gastric Cancer
|
April 2009 | Phase 1 |
NCT00536809 | GlaxoSmithKline |
Neoplasms, Colorectal
|
September 26, 2007 | Phase 1 |
NCT00130936 | AHS Cancer Control Alberta |
Gastric Cancer|Esophageal Cancer|Tumors
|
October 2005 | Phase 1|Phase 2 |
NCT04701281 | AllVascular |
Liver Metastasis Colon Cancer
|
June 20, 2019 | Phase 1|Phase 2 |
NCT00354601 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
January 2006 | Phase 2 |
NCT00296062 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 2006 | Phase 1 |
NCT05382442 | Akeso |
Metastatic Colorectal Cancer
|
July 27, 2022 | Phase 2 |
NCT01112826 | Sun Yat-sen University |
Breast Cancer
|
April 23, 2010 | Phase 3 |
NCT04745975 | Fudan University |
Triple Negative Breast Cancer
|
February 1, 2021 | Phase 2 |
NCT03465202 | Newcastle-upon-Tyne Hospitals NHS Trust|University of Newcastle Upon-Tyne |
Breast Cancer|Colorectal Cancer
|
May 2016 | Phase 4 |
NCT00363584 | University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI) |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer
|
March 2006 | Phase 3 |
NCT02380131 | Hebei Medical University |
HER-2 Positive Gastric Cancer|Liver Metastasis
|
February 2013 | Phase 4 |
NCT00686166 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
February 2009 | Phase 2 |
NCT04400695 | RemeGen Co., Ltd. |
Breast Cancer
|
September 29, 2020 | Phase 3 |
NCT00280761 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Colorectal Cancer
|
December 2003 | |
NCT00194727 | University of Washington|Hoffmann-La Roche|Pfizer |
Breast Neoplasm
|
May 2002 | Phase 2 |
NCT00049335 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
February 2003 | Phase 2 |
NCT03299660 | Peter MacCallum Cancer Centre, Australia |
Rectal Cancer
|
April 30, 2018 | Phase 2 |
NCT00227656 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2005 | Phase 2 |
NCT00798252 | Bristol-Myers Squibb |
Advanced Cancer
|
March 2009 | Phase 1 |
NCT01032850 | New Mexico Cancer Care Alliance|Bayer |
Hepatocellular Carcinoma
|
September 2009 | Phase 2 |
NCT02359058 | Eli Lilly and Company |
Stomach Neoplasms
|
February 2015 | Phase 1 |
NCT03257163 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Epstein-Barr Virus Positive|Gastric Adenocarcinoma|Mismatch Repair Protein Deficiency|Stage IB Gastric Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage IIA Gastric Cancer AJCC v7|Stage IIB Gastric Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7|Stage IIIC Gastric Cancer AJCC v7
|
September 29, 2017 | Phase 2 |
NCT04083365 | AUSL Romagna Rimini|AstraZeneca|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
RECTAL CANCER
|
January 1, 2020 | Phase 2 |
NCT00411762 | Yale University|PhytoCeutica|National Comprehensive Cancer Network|Roche Pharma AG |
Pancreatic Cancer
|
December 2006 | Phase 1|Phase 2 |
NCT00828672 | Universitaire Ziekenhuizen KU Leuven |
Locally Advanced Rectal Cancer
|
June 2009 | Phase 2 |
NCT03351296 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France |
Pancreatic Cancer
|
February 9, 2018 | Phase 2 |
NCT00069108 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2003 | Phase 3 |
NCT04351867 | LiNing|Henan Cancer Hospital |
Stomach Neoplasms
|
September 2020 | Phase 3 |
NCT02893540 | Ruijin Hospital |
Colorectal Cancer
|
September 2016 | Phase 2|Phase 3 |
NCT03387085 | ImmunityBio, Inc. |
Triple Negative Breast Cancer
|
March 16, 2018 | Phase 1|Phase 2 |
NCT00209092 | Emory University|Georgia Center for Oncology Research & Education|Sanofi |
Breast Cancer
|
August 2006 | Phase 2 |
NCT00807859 | Amgen |
Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors
|
March 9, 2009 | Phase 1 |
NCT02973386 | Sun Yat-sen University |
Local Advanced High Risk Nasopharyngeal Carcinoma
|
January 2017 | Phase 3 |
NCT00440167 | PD Dr. med. Volker Heinemann|Roche Pharma AG|Ludwig-Maximilians - University of Munich |
Pancreatic Cancer
|
June 2006 | Phase 3 |
NCT03136406 | ImmunityBio, Inc. |
Pancreatic Cancer
|
August 14, 2017 | Phase 1|Phase 2 |
NCT05238831 | OHSU Knight Cancer Institute|Oregon Health and Science University|Genentech, Inc. |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Ovarian Carcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Refractory Breast Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma|Stage III Ovarian Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Unresectable Malignant Solid Neoplasm|Unresectable Ovarian Carcinoma
|
December 1, 2022 | Phase 2 |
NCT00095901 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Roche Pharma AG |
Head and Neck Cancer
|
June 2004 | Phase 2 |
NCT04430738 | Seagen Inc. |
Colorectal Carcinoma|Gastric Adenocarcinoma|GEJ Adenocarcinoma|Esophageal Adenocarcinoma|Cholangiocarcinoma|Gallbladder Carcinoma
|
September 15, 2020 | Phase 1|Phase 2 |
NCT00118105 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Colorectal Cancer|Metastatic Cancer
|
November 2006 | Phase 2 |
NCT02648425 | Aslan Pharmaceuticals |
Solid Tumor
|
August 5, 2014 | Phase 1 |
NCT04202978 | Zhongshan Hospital Xiamen University |
Hepatic Metastasis of Colorectal Cancer
|
March 1, 2020 | Phase 1|Phase 2 |
NCT04401709 | Samsung Medical Center |
Biliary Tract Cancer
|
April 1, 2021 | Phase 3 |
NCT01041404 | Hoffmann-La Roche|Chugai Pharmaceutical |
Gastric Cancer
|
September 2005 | Phase 3 |
NCT04333706 | University of Florida|National Cancer Institute (NCI) |
Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell
|
September 26, 2020 | Phase 1|Phase 2 |
NCT04095390 | Jinming Yu|Jiangsu HengRui Medicine Co., Ltd.|Shandong Cancer Hospital and Institute |
Metastatic Breast Cancer|HER2-positive Breast Cancer
|
September 30, 2019 | Phase 2 |
NCT01921751 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer
|
August 2013 | Phase 2 |
NCT00082433 | R-Pharm |
Cancer|Breast Cancer
|
November 2003 | Phase 3 |
NCT01302613 | University of Texas Southwestern Medical Center |
Stage II Rectal Cancer|Stage III Rectal Cancer
|
March 2011 | Phase 1|Phase 2 |
NCT03125980 | Fudan University |
Locally Advanced Colon Cancer
|
May 2017 | Phase 3 |
NCT00024102 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group |
Breast Cancer
|
September 2001 | Phase 3 |
NCT00263705 | Jules Bordet Institute |
Elderly Patients|Breast Cancer
|
January 2003 | Phase 2 |
NCT03381352 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Anal Cancer
|
December 2, 2015 | Phase 2 |
NCT04296162 | Fudan University |
Breast Cancer
|
March 1, 2019 | Phase 2 |
NCT04607421 | Pfizer|Ono Pharmaceutical Co. Ltd|Merck KGaA, Darmstadt, Germany |
Neoplasms
|
December 21, 2020 | Phase 3 |
NCT02704520 | Royal Marsden NHS Foundation Trust |
Rectal Cancer
|
March 2016 | Phase 2|Phase 3 |
NCT00869570 | Swiss Group for Clinical Cancer Research |
Colorectal Cancer
|
March 2009 | Phase 1|Phase 2 |
NCT05262335 | Ruijin Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Gastrointestinal Tumors
|
December 1, 2021 | Phase 2 |
NCT02025192 | Seagen Inc. |
HER2 Positive Metastatic Breast Cancers
|
December 31, 2013 | Phase 1 |
NCT02024009 | University of Oxford|Celgene|Cancer Research UK |
Pancreatic Neoplasms (Locally Advanced Non-metastatic)
|
March 2016 | Phase 1|Phase 2 |
NCT03424005 | Hoffmann-La Roche|Seagen Inc.|Gilead Sciences |
Triple Negative Breast Cancer
|
April 2, 2018 | Phase 1|Phase 2 |
NCT05451719 | Fudan University |
Colorectal Cancer|Colorectal Cancer Stage IV
|
July 2022 | Phase 2 |
NCT00005908 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasm
|
June 2000 | Phase 2 |
NCT00212615 | Odense University Hospital |
C04.588.274.476.411.307
|
February 2004 | Phase 2|Phase 3 |
NCT04263298 | Herui Yao|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Metastatic Breast Cancer
|
May 1, 2018 | Phase 3 |
NCT00983268 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|National Comprehensive Cancer Network |
Pancreatic Cancer|Periampullary Adenocarcinoma
|
October 2009 | Phase 1 |
NCT05042791 | Jiangxi Provincial Cancer Hospital |
HER2-positive Metastatic Breast Cancer
|
March 1, 2022 | Phase 2 |
NCT03501979 | University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Johns Hopkins University|Seagen Inc.|University of Michigan|Georgetown University|University of California, San Francisco|University of Chicago|Indiana University|University of Washington|University of Texas |
Metastatic Breast Cancer|Leptomeningeal Disease
|
February 20, 2019 | Phase 2 |
NCT04363801 | Leap Therapeutics, Inc.|BeiGene |
Gastric Cancer|Gastric Adenocarcinoma|GastroEsophageal Cancer
|
July 29, 2020 | Phase 2 |
NCT00083525 | Heidelberg Pharma AG|United States Department of Defense |
Advanced Malignancies
|
May 2004 | Phase 1 |
NCT03923166 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer
|
April 19, 2019 | Phase 2 |
NCT03111732 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Biliary Tract Neoplasms|Cholangiocarcinoma|Bile Duct Cancer|Liver Cancer|Gallbladder Cancer
|
June 14, 2017 | Phase 2 |
NCT01249638 | Ludwig-Maximilians - University of Munich|Roche Pharma AG |
Colorectal Cancer Metastatic
|
December 2010 | Phase 3 |
NCT02244489 | Sierra Oncology, Inc. |
Relapsed+Refractory Metastatic Pancreatic Ductal Adenocarcinoma
|
November 5, 2014 | Phase 1 |
NCT01552967 | Sixth Affiliated Hospital, Sun Yat-sen University |
Colorectal Adenocarcinoma
|
March 2012 | Phase 2 |
NCT01705002 | Lipomedix Pharmaceuticals Inc. |
Cancer|Solid Tumor|Metastatic Colorectal Cancer (mCRC)
|
October 2012 | Phase 1 |
NCT00148876 | German Breast Group|Hoffmann-La Roche |
Breast Cancer
|
September 2003 | Phase 3 |
NCT00437073 | GlaxoSmithKline |
Neoplasms, Breast
|
May 2007 | Phase 2 |
NCT03006705 | Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb |
Gastric Cancer
|
January 31, 2017 | Phase 3 |
NCT01145404 | National Center for Tumor Diseases, Heidelberg |
GastroEsophageal Cancer
|
June 2010 | Phase 2 |
NCT00242788 | AstraZeneca |
Colorectal Cancer
|
February 2004 | Phase 1|Phase 2 |
NCT00095641 | Southwest Oncology Group|National Cancer Institute (NCI) |
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Oropharynx
|
Phase 2 | |
NCT03518242 | Fred Hutchinson Cancer Center|GlaxoSmithKline |
Breast Cancer Female|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
June 6, 2018 | Phase 1 |
NCT03901339 | Gilead Sciences |
Metastatic Breast Cancer
|
May 8, 2019 | Phase 3 |
NCT05360277 | Yanhong Deng|Sun Yat-sen University |
Metastatic Colorectal Cancer
|
December 1, 2022 | Phase 2 |
NCT00107250 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Colorectal Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
January 13, 2005 | Phase 1 |
NCT01873833 | University of Southern California|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
July 29, 2013 | Phase 2 |
NCT00642603 | Hoffmann-La Roche |
Colorectal Cancer
|
May 2008 | Phase 2 |
NCT01696695 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2011 | |
NCT00193128 | SCRI Development Innovations, LLC|Sanofi-Synthelabo|Aventis Pharmaceuticals |
Esophagus Cancer
|
April 2004 | Phase 1|Phase 2 |
NCT00274768 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
April 2004 | Phase 2 |
NCT02368860 | National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore |
Pancreatic Cancer
|
September 17, 2013 | Phase 1 |
NCT00717990 | University Hospital of Crete |
Metastatic Colorectal Cancer
|
April 2008 | Phase 2 |
NCT02494596 | Hoffmann-La Roche |
Solid Tumor
|
January 2004 | Phase 1 |
NCT04929028 | National Cancer Institute (NCI) |
AIDS-Related Anal Carcinoma|Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Margin Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|HIV Infection|Rectal Squamous Cell Carcinoma|Stage I Anal Cancer AJCC v8|Stage II Anal Cancer AJCC v8|Stage II Rectal Cancer AJCC v8|Stage IIA Anal Cancer AJCC v8|Stage IIA Rectal Cancer AJCC v8|Stage IIB Anal Cancer AJCC v8|Stage IIB Rectal Cancer AJCC v8|Stage IIC Rectal Cancer AJCC v8|Stage III Anal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Anal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Anal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Anal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8
|
November 23, 2021 | Phase 2 |
NCT00121836 | Hoffmann-La Roche |
Breast Cancer
|
June 2005 | Phase 4 |
NCT00201825 | Tony Bekaii-Saab|Roche Pharma AG|Ohio State University Comprehensive Cancer Center |
Lung Cancer|Non-Small-Cell Lung Carcinoma
|
December 2004 | Phase 2 |
NCT00468585 | Memorial Sloan Kettering Cancer Center |
Breast Cancer
|
June 2005 | Phase 1|Phase 2 |
NCT02000882 | US Oncology Research|Novartis Pharmaceuticals |
Brain Metastases|Breast Cancer|Metastatic Breast Cancer
|
May 29, 2014 | Phase 2 |
NCT02083653 | Symphogen A+S |
Metastatic Colorectal Cancer
|
March 6, 2014 | Phase 2 |
NCT03858972 | Odonate Therapeutics, Inc. |
Breast Cancer
|
February 5, 2019 | Phase 2 |
NCT00346099 | NSABP Foundation Inc|Amgen |
Rectal Cancer|Neoplasm Metastasis
|
June 2006 | Phase 2 |
NCT02795988 | Imugene Limited |
Gastrointestinal Neoplasms|Adenocarcinoma
|
August 30, 2017 | Phase 1|Phase 2 |
NCT01315431 | Genta Incorporated |
Solid Tumor
|
March 2011 | Phase 1 |
NCT02897050 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
September 2016 | Phase 2 |
NCT03734029 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
December 27, 2018 | Phase 3 |
NCT00745134 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Rectal Carcinoma|Stage IIA Rectal Cancer AJCC v7|Stage IIB Rectal Cancer AJCC v7|Stage IIC Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7
|
August 11, 2008 | Phase 2 |
NCT00026442 | Pharmatech Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
November 2001 | Phase 2 |
NCT02085005 | Sanofi|Regeneron Pharmaceuticals |
Colorectal Cancer Metastatic
|
March 2014 | Phase 2 |
NCT02726399 | Memorial Sloan Kettering Cancer Center |
Gastric Cancer|Gastroesophageal Junction Cancer
|
March 18, 2016 | Phase 2 |
NCT04721977 | Merck Sharp & Dohme LLC |
Breast Cancer
|
April 8, 2021 | Phase 2 |
NCT01118377 | Hoffmann-La Roche|Pediatric Brain Tumor Consortium |
Brainstem Glioma
|
May 2007 | Phase 2 |
NCT01399190 | Hoffmann-La Roche |
Colorectal Cancer
|
July 2011 | |
NCT02608073 | Hoffmann-La Roche |
Nasopharyngeal Cancer
|
November 2004 | Phase 2 |
NCT01918852 | Dutch Colorectal Cancer Group|Nordic Pharma SAS |
Colorectal Cancer|Metastases
|
December 2013 | Phase 3 |
NCT01474187 | Fudan University |
Rectal Cancer
|
November 2011 | Phase 1 |
NCT02355379 | Federation Francophone de Cancerologie Digestive |
Colonic Adenocarcinoma
|
January 2015 | Phase 3 |
NCT04534218 | Centre Hospitalier Universitaire de Besancon|Bayer |
Colo-rectal Cancer|Metastatic Cancer
|
October 16, 2020 | Phase 2 |
NCT04295317 | Shanghai Zhongshan Hospital |
Intrahepatic Cholangiocarcinoma
|
August 1, 2020 | Phase 2 |
NCT01754623 | H. Lee Moffitt Cancer Center and Research Institute |
Pancreatic Cancer
|
February 2013 | Phase 2 |
NCT00151047 | University of Michigan Rogel Cancer Center |
Prostate Cancer
|
March 2003 | Phase 2 |
NCT00260364 | Royal Marsden NHS Foundation Trust|Professor Cunningham´s Clinical Research Fund|Hoffmann-La Roche |
Pancreatic Cancer
|
November 2005 | Phase 1|Phase 2 |
NCT02419495 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma
|
June 26, 2015 | Phase 1 |
NCT00640081 | Cheryl Pugh|Medical Research Council |
Colorectal Cancer
|
July 2007 | Phase 2 |
NCT05228431 | Zhen-Hai Lu|Sun Yat-sen University |
Advanced Rectal Cancer
|
December 1, 2022 | Phase 2 |
NCT01843452 | Centre Hospitalier Universitaire Vaudois |
Carcinoma of Anal Canal
|
December 2012 | Phase 2 |
NCT00050167 | M.D. Anderson Cancer Center|Roche Pharma AG |
Breast Cancer
|
November 2002 | Phase 1 |
NCT01369433 | AVEO Pharmaceuticals, Inc. |
Solid Tumors
|
June 2010 | Not Applicable |
NCT03197584 | ImmunityBio, Inc. |
Ovarian Cancer
|
December 2017 | Phase 1|Phase 2 |
NCT01152710 | Institute of Oncology Ljubljana |
Resectable Rectal Cancer Clinical Stage II and III
|
June 2004 | Phase 2 |
NCT02205047 | European Organisation for Research and Treatment of Cancer - EORTC |
Malignant Neoplasm of Stomach|Malignant Neoplasm of Cardio-esophageal Junction of Stomach|Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
|
July 15, 2015 | Phase 2 |
NCT01026142 | Hoffmann-La Roche |
Breast Cancer
|
January 26, 2010 | Phase 3 |
NCT00570908 | Baylor Breast Care Center |
Breast Cancer
|
February 2009 | Phase 2 |
NCT00153907 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Breast Cancer
|
March 2002 | Phase 1 |
NCT02483247 | Sumitomo Pharma Oncology, Inc. |
Cancer
|
September 2015 | Phase 1 |
NCT00297141 | Austrian Breast & Colorectal Cancer Study Group|Sanofi-Synthelabo|Hoffmann-La Roche |
Rectal Cancer
|
October 2004 | Phase 2 |
NCT00003902 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
March 1999 | Phase 1|Phase 2 |
NCT00544011 | Hopital Jean Minjoz|National Cancer Institute (NCI) |
Colorectal Cancer
|
April 2007 | Phase 2 |
NCT01442155 | Hoffmann-La Roche |
Colorectal Cancer
|
October 2011 | |
NCT00717951 | Academy Military Medical Science, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Advanced Breast Cancer
|
May 2008 | Phase 2 |
NCT01159171 | Hoffmann-La Roche |
Colorectal Cancer
|
January 2006 | Phase 2 |
NCT04866108 | Beijing Friendship Hospital |
Unresectable Metastatic Colorectal Cancer
|
December 8, 2021 | Phase 2 |
NCT04464174 | MedSIR|Hoffmann-La Roche |
Triple Negative Breast Cancer
|
October 8, 2020 | Phase 2 |
NCT01468389 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Gastric Cancer
|
November 2011 | Phase 3 |
NCT01534546 | Peking University|Taiho Pharmaceutical Co., Ltd. |
Advanced Gastric Carcinoma
|
March 2012 | Phase 3 |
NCT01898104 | National Cancer Institute, Naples |
Colorectal Cancer
|
May 2012 | Phase 1|Phase 2 |
NCT00719550 | Amgen |
Esophagogastric Junction Adenocarcinoma|Gastric Cancer|Esophageal Cancer
|
February 2009 | Phase 1|Phase 2 |
NCT00320749 | Tony Bekaii-Saab|University of Michigan Rogel Cancer Center|Ohio State University Comprehensive Cancer Center |
Pancreatic Cancer
|
December 2005 | Phase 1 |
NCT01463982 | Hanmi Pharmaceutical Company Limited |
Solid Tumor|Advanced Cancer
|
December 2010 | Phase 1 |
NCT04089631 | Technische Universität Dresden |
Colon Cancer Stage II
|
June 26, 2020 | Phase 3 |
NCT00961571 | Georgetown University|Pfizer |
Metastatic Colorectal Cancer
|
August 2009 | Phase 2 |
NCT01777945 | Hoffmann-La Roche |
Breast Cancer
|
December 2012 | |
NCT00689702 | Institute of Oncology Ljubljana |
Rectal Cancer
|
February 2007 | Phase 2 |
NCT01360593 | David A. Clump, MD, PhD|University of Pittsburgh |
Pancreatic Cancer
|
July 25, 2011 | Phase 2 |
NCT05307198 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Rectal Neoplasms
|
April 25, 2022 | Phase 2 |
NCT00075556 | GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI) |
Colorectal Cancer
|
January 2002 | Phase 2 |
NCT03280407 | Zealand University Hospital |
Colorectal Neoplasm|Colorectal Cancer|Rectal Neoplasms|Chemotherapy Effect|Intestinal Disease|Intestinal Neoplasms|Rectal Cancer
|
March 1, 2017 | Phase 2 |
NCT00635323 | Pfizer |
Carcinoma, Hepatocellular
|
November 2002 | Phase 2 |
NCT00660426 | Washington University School of Medicine |
Advanced Gastrointestinal Malignancies|Solid Tumors
|
March 2005 | Phase 1 |
NCT04198727 | Centre Antoine Lacassagne|Cerbaliance |
Breast Neoplasm Malignant Female
|
July 20, 2020 | Not Applicable |
NCT00707278 | University of Utah |
Cancer|Pancreas
|
September 2005 | Phase 1 |
NCT03161522 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Gastric Adenocarcinoma|Oligometastasis|Stage IV Esophageal Adenocarcinoma AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7
|
February 19, 2018 | Phase 2 |
NCT02288195 | Sun Yat-sen University|Shantou Central Hospital|Liaoning Tumor Hospital & Institute|The First Affiliated Hospital with Nanjing Medical University|Fujian Cancer Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Guangzhou Medical University|Guangdong Provincial People´s Hospital|Cancer Hospital of Guangxi Medical University|Meizhou People´s Hospital|Henan Cancer Hospital|Affiliated Cancer Hospital of Shantou University Medical College|Hubei Cancer Hospital|The First Affiliated Hospital of Kunming Medical College|Longyan City First Hospital|Shengjing Hospital|Zhejiang Cancer Hospital|Jiangmen Central Hospital|West China Hospital|The Third Affiliated Hospital of Kunming Medical College. |
Rectal Neoplasms
|
August 13, 2014 | Phase 3 |
NCT00176787 | University of Michigan Rogel Cancer Center|Hoffmann-La Roche |
Rectal Cancer
|
October 2000 | Phase 2 |
NCT00524069 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Pancreatic Cancer
|
January 2007 | Not Applicable |
NCT00658840 | National Cancer Center, Korea |
Pancreatic Cancer
|
June 2006 | Phase 2 |
NCT00634751 | University of Wisconsin, Madison|Bayer|Sanofi |
Pancreatic Neoplasms|Bile Duct Neoplasms
|
February 2008 | Phase 1|Phase 2 |
NCT00543842 | M.D. Anderson Cancer Center|Genentech, Inc. |
Rectal Cancer
|
December 2007 | Phase 1 |
NCT05288777 | University of Virginia |
Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III
|
May 2022 | Phase 2|Phase 3 |
NCT00493636 | Accelerated Community Oncology Research Network|Amgen |
Breast Cancer
|
June 2007 | Phase 2 |
NCT01295086 | Odense University Hospital|Aalborg University Hospital|Aarhus University Hospital|Rigshospitalet, Denmark |
Adenocarcinoma
|
March 2011 | Not Applicable |
NCT00447330 | Duke University|Hoffmann-La Roche|Sanofi|Genentech, Inc. |
Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis
|
February 2007 | Phase 2 |
NCT03563144 | ImmunityBio, Inc. |
Metastatic Pancreatic Cancer
|
August 2018 | Phase 2 |
NCT02335411 | Merck Sharp & Dohme LLC |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
February 3, 2015 | Phase 2 |
NCT05249101 | CG Pharmaceuticals, Inc |
Metastatic Pancreatic Adenocarcinoma
|
July 1, 2022 | Phase 1|Phase 2 |
NCT02565641 | Hoffmann-La Roche |
Pancreatic Cancer
|
March 2003 | Phase 2 |
NCT04940546 | Sun Yat-sen University |
Colorectal Cancer Metastatic
|
June 16, 2021 | Phase 1|Phase 2 |
NCT00486356 | University of Nebraska|National Cancer Institute (NCI) |
Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Liver Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
October 2004 | Phase 1 |
NCT02491697 | The First People´s Hospital of Changzhou |
Breast Cancer
|
February 2016 | Phase 2 |
NCT01290718 | Hoffmann-La Roche |
Breast Cancer
|
December 2011 | Phase 2 |
NCT04340401 | Peking University Cancer Hospital & Institute |
Rectal Cancer
|
May 25, 2020 | Phase 2 |
NCT00070213 | Medical Research Council|University of Leeds |
Colorectal Cancer
|
September 2003 | Phase 3 |
NCT00634088 | R-Pharm|GlaxoSmithKline |
Locally Advanced or Metastatic Breast Cancer
|
June 2008 | Phase 1 |
NCT01774786 | Hoffmann-La Roche |
Gastric Cancer
|
June 10, 2013 | Phase 3 |
NCT05062317 | M.D. Anderson Cancer Center |
Liver Metastases
|
April 26, 2022 | Phase 2 |
NCT04564898 | Gruppo Oncologico del Nord-Ovest |
Colorectal Cancer Metastatic
|
January 25, 2022 | Phase 1|Phase 2 |
NCT01718873 | National Cancer Institute, Naples |
Colorectal Cancer
|
May 2012 | Phase 3 |
NCT05342792 | Sun Yat-sen University|Tongji Hospital|Wuhan Union Hospital, China|Xiangya Hospital of Central South University|Affiliated Cancer Hospital of Guizhou Medical University|Cancer Hospital of Guangxi Medical University|First People´s Hospital of Foshan|Chongqing University Cancer Hospital|Hubei Cancer Hospital|Hunan Cancer Hospital|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Fifth Affiliated Hospital, Sun Yat-Sen University|Shandong Provincial Hospital |
Nasopharyngeal Carcinoma
|
April 17, 2022 | Phase 3 |
NCT00446290 | Asan Medical Center |
Stomach Cancer
|
March 2006 | Phase 1 |
NCT04395989 | Fudan University |
TNBC - Triple-Negative Breast Cancer
|
May 15, 2020 | Phase 2 |
NCT03684863 | Shandong Cancer Hospital and Institute |
HER2-positive Breast Cancer
|
October 2018 | Phase 2 |
NCT00684216 | The Netherlands Cancer Institute |
Breast Cancer
|
April 2008 | Phase 2|Phase 3 |
NCT00235235 | Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Walther Cancer Institute |
Breast Cancer
|
September 2005 | |
NCT01498458 | German Breast Group |
Metastatic Breast Cancer
|
October 2010 | Phase 1 |
NCT00270491 | ARCAGY+ GINECO GROUP |
Breast Cancer|Neoplasm Metastasis
|
December 2005 | Phase 2 |
NCT00483366 | University of Nebraska|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2006 | Phase 1 |
NCT00435409 | Pfizer |
Breast Neoplasms
|
February 2007 | Phase 3 |
NCT00037609 | M.D. Anderson Cancer Center|Cell Pathways |
Breast Neoplasms|Metastases, Neoplasm
|
January 2001 | Phase 1|Phase 2 |
NCT01591733 | Massachusetts General Hospital|National Cancer Institute (NCI) |
Pancreatic Cancer
|
May 2012 | Phase 2 |
NCT00787787 | University of Washington|National Cancer Institute (NCI) |
Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer
|
September 2008 | Phase 2 |
NCT02008656 | Memorial Sloan Kettering Cancer Center|Colon and Rectal Surgery Inc.|The Cleveland Clinic|John Muir Health|Oregon Health and Science University|St. Joseph Hospital of Orange|University of California, Irvine|University of California, San Francisco|University of Chicago|University of South Florida|University of Vermont|University of Washington|Medstar Health Research Institute|Washington University School of Medicine|Creighton University Medical Center|The Methodist Hospital Research Institute|University of Rochester|University of Virginia|St. Paul´s Hospital|St. Joseph, Florida|Cleveland Clinic Florida|University of Colorado, Denver|University of Michigan |
Rectal Cancer
|
November 2013 | Phase 2 |
NCT00732810 | Merck Sharp & Dohme LLC |
Breast Neoplasms|Carcinoma, Non-Small-Cell Lung
|
July 2008 | Phase 2 |
NCT02216149 | Heikki Joensuu|Helsinki University Central Hospital |
Esophagus Cancer|Stomach Cancer|Small Bowel Cancer|Colon Cancer|Rectum Cancer
|
January 2015 | Phase 2 |
NCT04787354 | Hallym University Medical Center |
Gastric Cancer
|
November 1, 2021 | Phase 3 |
NCT00016926 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
April 2001 | Phase 2 |
NCT00062426 | Prologue Research International|National Cancer Institute (NCI) |
Colorectal Cancer
|
May 2003 | Phase 3 |
NCT04366713 | Puma Biotechnology, Inc. |
HER2 Amplified Breast Cancer
|
June 30, 2020 | Phase 2 |
NCT05507658 | Xijing Hospital |
Locally Advanced Gastric Adenocarcinoma
|
July 18, 2022 | Phase 2 |
NCT01245582 | Sanofi |
Hepatic Neoplasm Malignant
|
July 2011 | Phase 3 |
NCT00321685 | National Cancer Institute (NCI) |
Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7
|
July 25, 2006 | Phase 2 |
NCT02595424 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Gastric Neuroendocrine Carcinoma|Intestinal Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Carcinoma
|
November 6, 2015 | Phase 2 |
NCT00477711 | Peking University|Merck Sharp & Dohme LLC |
Gastric Cancer
|
March 2007 | Phase 2 |
NCT00423696 | UNICANCER |
Colorectal Cancer
|
March 23, 2006 | Phase 2 |
NCT00733616 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Sanofi|Hoffmann-La Roche |
Gastric Cancer
|
November 2008 | Phase 2 |
NCT05484375 | Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Hunan Cancer Hospital |
Metastatic Nasopharyngeal Carcinoma
|
September 2022 | Phase 2 |
NCT02199236 | Memorial Sloan Kettering Cancer Center |
Rectal or Anal Cancer
|
July 2014 | Phase 1 |
NCT01534637 | Wake Forest University Health Sciences|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC |
Extrahepatic Bile Duct Cancer|Nausea|Vomiting|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
August 2006 | Phase 2 |
NCT00337103 | Eisai Inc. |
Metastatic Breast Cancer
|
September 20, 2006 | Phase 3 |
NCT01064999 | Fudan University|Zhejiang Cancer Hospital|First People Hospital of Zhejiang|RenJi Hospital |
Rectal Cancer
|
March 2010 | Phase 2|Phase 3 |
NCT04922008 | Fudan University |
Breast Cancer
|
July 1, 2021 | Phase 2 |
NCT03472365 | Jiangsu HengRui Medicine Co., Ltd. |
Gastric Cancer|GastroEsophageal Cancer
|
April 2, 2018 | Phase 2 |
NCT01804790 | UNICANCER |
Cancer of the Rectum
|
January 2012 | Phase 3 |
NCT04158258 | Hoffmann-La Roche|Latin American Cooperative Oncology Group |
Breast Cancer
|
February 21, 2020 | |
NCT03435666 | Qilu Pharmaceutical Co., Ltd. |
Colon Cancer|Breast Cancer
|
May 2018 | Phase 1 |
NCT01267240 | National Cancer Institute (NCI) |
Paranasal Sinus Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma
|
December 2010 | Phase 2 |
NCT01683422 | Loma Linda University |
Pancreatic Cancer
|
January 2, 2013 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 695.70 mM ; Need ultrasonic)
H 2 O : ≥ 33.33 mg/mL ( 92.75 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.7828 mL | 13.9140 mL | 27.8280 mL |
5 mM | 0.5566 mL | 2.7828 mL | 5.5656 mL |
10 mM | 0.2783 mL | 1.3914 mL | 2.7828 mL |
Add each solvent one by one: PBS
Solubility: 25 mg/mL (69.57 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution